increas
number
studi
biolog
role
oligosaccharid
glycoprotein
occur
last
year
btsed
larg
use
f
glycosyl
inhibitor
review
discuss
commonli
use
inhibitor
provid
context
discuss
aspect
structur
biosynthesi
oligosaccharid
glycoprotein
describ
section
discuss
includ
intracellular
traffic
glycoprotein
sinc
close
link
biosynthesi
role
oligosaccharid
glycoprotein
glycosyl
protein
oligosaccharid
preassembl
lipidcarri
dolicholdiphosph
transfer
protein
inhibitor
socal
dolichol
pathway
address
section
inhibitor
give
rise
nonor
underglycosyl
protein
follow
transfer
protein
oligosaccharid
process
matur
form
inhibit
process
pathway
mainli
glycosidas
inhibitor
thu
give
rise
protein
glycosyl
immatur
oligosaccharid
section
biolog
effect
inhibitor
studi
numer
system
certain
secret
glycoprotein
lysosom
glycoprotein
prefer
target
studi
glycosyl
inhibitor
refrain
discuss
glycoprotein
extens
sinc
cover
review
schwarz
datema
olden
et
al
elbein
olden
et
al
kornfeld
kornfeld
von
figura
hasilik
review
concentr
biolog
effect
inhibitor
seen
virusinfect
cell
section
proven
use
system
delin
sever
aspect
biosynthesi
membran
glycoprotein
biolog
role
protein
glycosyl
turn
expect
elucid
process
viral
system
would
assist
develop
agent
exert
antivir
effect
section
structur
oligosaccharid
chain
viral
glycoprotein
classifi
two
group
structur
coval
linkag
oligosaccharid
polypeptid
backbon
kornfeld
kornfeld
montreuil
sharon
li
first
class
call
asparagineor
nlink
oligosaccharid
nglycosid
link
nacetylglucosamin
amid
nitrogen
asparagin
second
class
call
olink
oligosaccharid
oglycosid
link
nacetylgalactosamin
serin
threonin
fig
latter
oligosaccharid
also
call
mucintyp
oligosaccharid
sinc
abund
mucin
nand
olink
oligosaccharid
contain
invari
structur
conjug
peptid
chain
call
inner
core
fig
inner
core
substitut
sugar
residu
give
rise
wide
varieti
oligosaccharid
thu
nlink
oligosaccharid
deriv
common
biosynthet
precursor
see
subdivid
three
group
fig
highmannos
oligosaccharid
contain
mannos
nacetylglucosamin
residu
heptasaccharid
occur
substitut
residu
link
nonreduc
termini
heptasaccharid
fig
ii
complextyp
oligosaccharid
ir
mannosyl
residu
innercor
ii
fig
attach
number
outer
chain
outer
chain
often
contain
trisaccharid
chain
occur
well
substitut
pattern
lead
socal
bi
tri
tetraand
pentaantennari
complextyp
oligosaccharid
addit
innermost
glcnac
residu
one
link
asparagin
usual
contain
residu
link
exampl
triantennari
structur
see
fig
iii
hybridtyp
oligosaccharid
present
oligomannosid
complextyp
structur
fig
glycoprotein
erythrocyt
membran
certain
embryon
cell
contain
poli
lactosamin
oligosaccharid
ie
complextyp
oligosaccharid
repeat
lactosamin
disaccharid
n
outer
branch
jfirnefelt
et
al
poli
lactosamin
oligosaccharid
substitut
larg
oligosaccharid
result
muramatsu
et
al
jfirnefelt
et
al
found
viral
glycoprotein
even
glycoprotein
virus
propag
embryon
cell
etchison
et
al
therefor
discuss
carbohydr
chain
olink
oligosaccharid
heterogen
structur
structur
galfl
core
iva
fig
commonli
occur
structur
two
simpl
exampl
shown
fig
olink
oligosaccharid
viral
glycoprotein
first
report
herp
simplex
viru
olofsson
et
al
olofsson
et
al
mous
hepat
viru
corona
viru
niemann
klenk
holm
et
al
vaccinia
viru
shida
dale
wherea
nlink
oligosaccharid
present
almost
viral
glycoprotein
viral
glycoprotein
known
contain
olink
oligosaccharid
glycoprotein
gicnaciasn
mous
hepat
viru
niemann
klenk
holm
et
al
structur
major
oligosaccharid
shown
fig
niemann
et
al
final
structur
nand
olink
oligosaccharid
determin
sever
factor
see
speciesspecif
structur
differ
occur
kept
mind
oligosaccharid
viral
glycoprotein
show
differ
structur
depend
celltyp
viru
propog
differ
nlink
complextyp
hybrid
oligosaccharid
includ
degre
branch
degre
sialyl
variat
type
glycosid
bond
peripher
sugar
sharon
li
kornfeld
kornfeld
extent
variat
structur
olink
oligosaccharid
viral
glycoprotein
known
necessari
suffici
condit
nglycosyl
protein
occurr
asparagin
tripeptid
sequenc
asnxser
thr
marshal
kornfeld
kornfeld
addit
requir
exposur
tripeptid
sequenc
special
secondari
structur
probabl
determin
access
peptid
oligosaccharid
transferas
thu
although
x
asnxser
thr
almost
amino
acid
prolin
forbidden
unfavour
conform
peptid
discuss
see
montreuil
role
polypeptid
structur
oligosaccharid
biosynthesi
suggest
experi
show
individu
glycosyl
site
particular
protein
may
carri
specif
oligosaccharid
see
specif
polypeptid
sequenc
requir
oglycolys
known
howev
sequenc
alaxalasers
alaxalathrthr
valprothr
propos
takayashu
et
al
acceptor
sequenc
transfer
coregalnac
residu
hydroxi
amino
acid
ser
thr
propos
question
melli
baenzig
instead
access
hydroxi
amino
acid
residu
galnactransf
enzym
higherord
structur
featur
polypeptid
chain
rather
short
characterist
amino
acid
sequenc
consid
critic
determin
transfer
galnac
residu
kessler
et
al
melli
baenzig
biosynthesi
nand
olink
oligosaccharid
use
glycosyltransferas
catalyz
transfer
sugar
residu
sugar
donor
hydroxyl
group
acceptor
substrat
sharon
li
kornfeld
kornfeld
sugar
donor
either
nucleotid
ester
sugar
dolichol
isoprenoid
alcohol
ester
monosaccharid
monophosph
tabl
base
sugar
transfer
enzym
call
galactosyl
transferas
mannosyl
transferas
etc
glycosyl
transferas
usual
specif
acceptor
substrat
anomer
linkag
form
fig
show
specif
two
differ
nacetylglucosaminyl
transferas
name
gicnac
transferas
ii
beyer
et
al
schachter
specif
glycosyl
transferas
found
support
gener
hypothesi
differ
enzym
requir
synthesi
glycosid
linkag
occur
oligosaccharid
glycoprotein
socal
one
linkageon
enzym
hypothesi
cf
roseman
subject
review
detail
kornfeld
kornfeld
hubbard
ivatt
schwarz
datema
kornfeld
kornfeld
biosynthesi
nlink
oligosaccharid
three
phase
discern
l
assembl
highmannos
oligosaccharid
membranebound
lipid
dolichol
diphosph
hem
transfer
oligosaccharid
protein
usual
nascent
polypeptid
chain
process
proteinbound
oligosaccharid
gener
complex
type
hybridtyp
highmannos
oligosaccharid
action
glycosidas
glycosyl
transferas
beyer
et
al
schachter
kornfeld
kornfeld
pathway
assembl
immedi
precursor
protein
glycosyl
refer
dolichol
pathway
shown
fig
enzym
dolichol
pathway
membranebound
appear
enrich
rough
endoplasm
reticulum
struck
lennarz
transfer
gicnacp
udpglcnac
donor
man
gdpman
manpdol
glc
udpgic
glcpdol
glcnac
udpgicnac
galnac
udpgalnac
gal
udpgal
fuc
gdpfuc
neuac
cmpneuac
note
biosynthesi
sugar
nucleotid
see
sharon
li
staneloni
et
al
parodi
leloir
glucosyl
lipidlink
oligosaccharid
facilit
effici
transfer
protein
spiro
et
al
staneloni
et
al
trimbl
et
al
wherea
peripher
mannos
residu
donat
manpdol
requir
transfer
oligosaccharid
protein
spiro
et
al
exampl
manpdol
format
prevent
intact
cell
glcnac
form
oligosaccharid
transfer
protein
chapman
et
al
chapman
et
al
turco
rearick
et
al
transfer
protein
nonglucosyl
highmannos
oligosaccharid
observ
see
eg
parodi
quesadaallu
yet
demonstr
viral
glycoprotein
see
also
romero
herscov
schwarz
datema
follow
transfer
oligosaccharid
protein
glucos
residu
remov
glucosidas
glucosidas
ii
fig
two
enzym
occur
endoplasm
reticulum
kornfeld
studi
inhibitor
deglucosyl
show
reaction
play
import
role
posttransl
fate
glycoprotein
exampl
deglucosyl
necessari
effici
movement
glycoprotein
golgi
apparatu
see
section
glycoprotein
stay
endoplasm
reticulum
exit
endoplasm
reticulum
slowli
mannos
trim
may
occur
endoplasm
reticulum
give
glcnac
structur
atkinson
kabcenel
kabcenel
atkinson
also
nonglucosyl
highmannos
oligosaccharid
may
transient
reglucosyl
endoplasm
reticulum
possibl
prevent
extens
mannos
trim
parodi
et
al
golgibound
mannosidas
remov
number
link
mannos
residu
give
rise
variou
highmannos
oligosaccharid
found
matur
glycoprotein
kornfeld
process
complexand
hybridtyp
oligosaccharid
occur
golgi
apparatu
remov
final
two
noncor
mannos
residu
cf
structur
ii
fig
requir
prior
addit
nacetylglucosamin
gicnac
transferas
shown
fig
beyer
et
al
schachter
kornfeld
kornfeld
intermedi
glcnacman
glcnac
fig
precursor
hybridtyp
structur
addit
glcnac
fllink
mannos
glcnac
transferas
iii
block
remov
noncor
mannos
ctmannosidas
ii
compound
form
action
ctmannosidas
ii
fig
substrat
glcnactransferas
ii
iii
fucosyl
transferas
transfer
fuc
asnlink
glcnac
fucosyl
transferas
absolut
requir
acceptor
nonsubstitut
r
gicnacgicnacasn
fig
initi
step
process
pathway
base
refer
cite
text
follow
step
shown
fig
fig
trim
mannos
residu
need
go
complet
shown
highmannos
oligosaccharid
product
occur
matur
glycoprotein
r
glcnac
branch
fucogyl
transferas
act
transfer
glcnac
glcnactransferas
addit
gal
galactosyl
transferas
glcnac
branch
schachter
beyer
et
al
assembl
simpl
biantennari
complextyp
oligosaccharid
complet
stepwis
addit
galactos
sialic
acid
exampl
fig
propos
pathway
suggest
branch
specif
galactosyl
sialyltransferas
ie
glycosyl
transferas
first
use
branch
contrast
branch
spatial
fix
one
orient
montreuil
suggest
galactosyl
branch
determin
fate
oligosaccharid
becom
biantennari
oligosaccharid
structur
ii
fig
poor
substrat
glcnactransferas
iv
initi
triantennari
structur
vella
et
al
narasimhan
et
al
blanken
et
al
joziass
et
al
joziass
et
al
thu
sequenti
action
glycosyl
transferas
high
substrat
specif
competit
enzym
common
substrat
factor
determin
ultim
structur
complextyp
oligosaccharid
actual
achiev
known
see
also
determin
extent
process
particular
cell
equip
set
glycosidas
glycosyl
transferas
henc
oligosaccharid
structur
genet
control
sharon
li
addit
rel
amount
glycosyl
enzym
probabl
metabol
control
thu
depend
metabol
state
host
cell
differ
oligosaccharid
could
isol
sindbi
viru
glycoprotein
e
l
obtain
viru
grown
cell
hakimi
atkinson
glucos
starvat
energi
depelet
affect
format
lipidlink
oligosaccharid
kaluza
turco
baumann
jahrei
spiro
et
al
griffin
et
al
effect
depend
celltyp
celldens
exampl
format
accumul
truncat
oligosaccharid
smaller
occur
oligosaccharid
could
glucosyl
transfer
protein
clear
cellular
glycosyl
machineri
produc
wide
varieti
differ
oligosaccharid
one
factor
determin
extent
process
may
interact
polypeptid
chain
cellular
process
enzym
primari
structur
polypeptid
chain
import
determin
carbohydr
structur
clearli
shown
viral
glycoprotein
individu
glycosyl
site
show
select
either
highmannos
complextyp
oligosaccharid
schwarz
klenk
hsieh
et
al
hsieh
et
al
savvidon
et
al
hsieh
robbin
mayn
et
al
review
pollack
atkinson
physic
access
oligosaccharid
fact
determin
extent
process
could
shown
sindbi
viru
glycoprotein
glycosyl
site
access
enzym
destin
acquir
moreprocessdd
complextyp
oligosaccharid
hsieh
et
al
note
one
intracellular
pathway
biosynthesi
rout
viral
glycoprotein
final
destin
occur
roth
et
al
roth
et
al
rindler
et
al
pfeiffer
et
al
see
also
addit
certain
glycosyl
transferas
may
present
particular
golgisubcompart
dunphi
rothman
goldberg
kornfeld
tartakoff
vassali
schachter
roth
et
al
gabel
bergman
dunphi
rothman
passag
golgi
system
glycoprotein
encount
biochem
distinct
subcompart
call
ci
region
glycoprotein
enter
golgi
medial
region
tran
region
glycoprotein
exit
golgi
enzym
carri
sequenti
process
nlink
oligosaccharid
found
occur
differ
subcompart
kornfeld
kornfeld
exampl
galactosyltransferas
berger
et
al
strou
berger
confin
tran
region
glcnactransferas
dunphi
et
al
concentr
medial
region
thu
final
structur
oligosaccharid
determin
competit
substrat
specif
glycosyl
transferas
also
compartment
organ
golgi
stack
certain
glycosyl
transferas
encount
distinct
compart
interest
question
associ
extens
compartmentalis
glycosyl
pathway
sugardonor
becom
avail
glycosyl
transferas
exampl
cmpneuac
synthes
nucleu
transport
cytoplasm
van
den
eijnden
wherea
sialyltransferas
occur
lumin
side
presum
tran
golgi
stack
kornfeld
kornfeld
shown
ratliv
golgivesicl
transloc
cmpneuac
across
golgi
membran
transloc
coupl
equimolar
exchang
cmp
sommer
hirschberg
deutscher
et
al
capasso
hirschberg
similar
mechan
found
golgi
membran
sugar
nucleotid
udpgal
gdpfuc
degrad
nucleosid
diphosph
nucleosid
diphosphatas
thiamin
pyrophosphatas
golgi
enzym
brendan
fleischer
monophosph
appear
requir
transloc
antiport
transloc
nucleosid
monophosph
deutscher
hirschberg
capasso
hirschberg
whether
similar
transloc
mechan
exist
endoplasm
reticulum
oligosaccharidelipid
synthesi
occur
investig
thu
udpglcnac
transloc
across
membran
vesicl
rough
endoplasm
reticulum
perez
hirschberg
howev
observ
suggest
transfer
gicnac
dolichol
even
synthesi
man
glcnac
occur
cytoplasm
face
endoplasm
reticulum
cf
kornfeld
kornfeld
discuss
mechan
requir
transloc
udpglcnac
assembl
gicnac
requir
dolichollink
sugar
donor
occur
lumin
face
also
lumin
face
endoplasm
reticulum
lipidlink
oligosaccharid
act
donor
protein
glycosyl
bergman
kuehl
udpglc
gdpman
transloc
known
interest
howev
vitamin
defici
caus
accumul
man
glcnac
rosso
et
al
synthesi
requir
manpdol
retinol
retinol
mannosylphosph
may
involv
protein
glycosyl
de
luca
et
al
bernard
et
al
exampl
transloc
mechan
man
frotcoutaz
et
al
propos
found
wide
accept
stoll
et
al
olink
oligosaccharid
synthes
without
involv
dolichollink
intermedi
thu
addit
first
galnac
udpgalnac
polypeptid
format
olink
oligosaccharid
proce
success
action
individu
transferas
act
directli
peptidebound
grow
oligosaccharid
indic
peptid
signal
requir
addit
first
galnac
incomplet
understood
biosynthesi
olink
oligosaccharid
probabl
occur
golgi
concomit
process
nlink
oligosaccharid
kim
et
al
ko
raghupathi
hanov
et
al
result
accord
studi
use
monensin
block
rout
glycoprotein
golgi
thu
glycoprotein
herp
simplex
viru
produc
presenc
monensin
found
devoid
olink
oligosaccharid
johnson
spear
howev
studi
vitro
galnac
transferas
isol
bhkcell
show
immatur
form
viral
glycoprotein
glycoprotein
yet
possess
fulli
process
nlink
complex
type
oligosaccharid
acquir
initi
galnac
residu
serafinicessi
et
al
therefor
possibl
initi
galnac
ad
ci
golgi
remaind
assembl
oglycosyl
oligosaccharid
take
place
medial
tran
region
golgi
simultan
addit
termin
sugar
nlink
oligosaccharid
inde
two
enzym
olink
oligosaccharid
synthesi
galnacand
galtransferas
could
separ
densiti
gradient
centrifug
galnac
termin
linkag
occur
ci
tran
golgi
elhamm
kornfeld
roth
thu
coregalnac
transfer
ci
golgi
peripher
galnac
ad
later
tran
golgi
factor
govern
structur
variabl
oglycosyl
oligoscharid
may
similar
govern
process
nlink
oligosaccharid
although
rigor
prove
thu
glycosyl
transferas
specif
sugar
nucleotid
acceptor
ie
oligosaccharid
enzym
establish
one
type
glycosid
linkag
roseman
word
inform
sequenc
monosaccharid
final
oligosaccharid
transfer
genom
specif
transferas
act
consecut
newli
ad
sugar
gener
suitabl
acceptor
subsequ
transferas
addit
compartment
organ
golgi
compens
defici
specif
see
evid
introduct
one
new
glycosyl
transferas
act
earli
biosynthesi
olink
oligosaccharid
implic
format
acceptor
oligosaccharid
subsequ
enzym
consequ
viru
would
code
enzym
might
consider
influenc
structur
oligosaccharid
assembl
olink
pentasaccharid
blood
group
activ
porcin
submaxillari
mucin
studi
detail
cf
beyer
et
al
review
enzym
engag
biosynthesi
purifi
character
scheme
assembl
pentasaccharid
present
fig
final
structur
associ
porcin
submaxillari
mucin
box
lower
part
figur
galnac
rthr
final
structur
oligosaccharld
fig
scheme
assembl
bloodgroup
areact
olink
oligosaccharid
porcin
submaxillari
mucin
pathway
format
oligosaccharid
indic
seri
thin
arrow
thick
arrow
indic
prefer
glycosyl
transferas
reaction
provid
kinet
properti
intracellular
amount
enzym
import
factor
determin
structur
oligosaccharid
dash
arrow
cross
bar
denot
forbidden
reaction
see
text
thefigur
drawn
roseman
ivatt
figur
evid
branch
biosynthet
pathway
may
lead
dead
end
product
thu
structur
result
reaction
g
inaccess
process
isol
subfract
mucin
addit
first
galnac
appear
sialyl
transferas
galactosyl
transferas
overlap
acceptor
specif
compet
proteinassoci
gainac
specif
glycosyltransferas
illustr
fact
neuacgalnac
oligosaccharid
form
reaction
accept
galactosyl
transferas
act
reaction
b
consequ
reaction
allow
result
dead
end
product
neuacgalnacprotein
appear
dead
end
product
show
competit
transferas
must
occur
howev
sever
line
evid
indic
major
enzym
engag
reaction
c
must
manipul
way
produc
structur
ivatt
roseman
evid
follow
studi
vitro
kinet
properti
rel
abund
glycosyl
transferas
cell
highli
prefer
enzym
reaction
establish
indic
broad
arrow
figur
clear
none
reaction
involv
assembl
pentasaccharid
trisaccharid
propos
reaction
e
highli
favour
vitro
properti
submaxillari
gland
glycosyl
transferas
sadler
et
al
fact
never
demonstr
mucin
carlson
ivatt
ii
sever
step
reaction
glycosyl
transferas
act
nonoptim
substrat
exampl
disaccharid
galgalnacserthr
better
substrat
trisaccharid
b
fucosyl
transferas
howev
oligosaccharid
fucosyl
reaction
f
becom
poor
substrat
sialyl
transferas
reaction
h
occur
word
data
provid
circumstanti
evid
glycosyl
transferas
act
format
pentasaccharid
regul
specif
higher
order
final
peptid
sequenc
import
glycosyl
determin
whether
glycosyl
take
place
also
direct
protein
differ
intracellular
compart
offer
number
possibl
structur
final
oligosaccharid
best
known
inhibitor
dolichol
pathway
discov
virtu
antivir
antibacteri
properti
schwarz
datema
target
drug
name
lipiddepend
transfer
sugar
sugar
phosphat
deriv
occur
glycosyl
envelop
glycoprotein
virus
bacteri
peptidoglycan
synthesi
subsequ
studi
mode
action
inhibitor
studi
biolog
consequ
inhibit
glycosyl
reli
larg
extent
use
virusinfect
cell
fact
mani
pioneer
studi
glycoprotein
biosynthesi
use
virusinfect
cell
model
system
altogeth
impli
wealth
data
viral
protein
glycosyl
sever
reaction
dolichol
pathway
studi
cellfre
system
rosner
et
al
howev
none
enzym
pathway
obtain
highli
purifi
form
contrast
enzym
involv
process
pathway
sadler
et
al
studi
mode
action
inhibitor
dolichol
pathway
depend
use
less
crude
cell
fraction
analysi
reaction
product
enzym
dolichol
pathway
host
enzym
ie
specifi
viru
howev
ultim
substrat
dolichol
pathway
proteinacceptor
viruscod
product
antivir
effect
inhibitor
protein
glycosyl
therefor
consequ
special
properti
particular
viral
glycoprotein
high
rate
viral
glycoprotein
biosynthesi
infect
cell
schwarz
datema
way
preferenti
antivir
effect
may
obtain
necessarili
specif
one
host
cell
protein
glycosyl
affect
well
extens
discuss
see
section
section
discuss
mainli
mode
action
wellknown
inhibitor
dolichol
pathway
name
sugar
analog
tunicamycin
compound
interf
dolichol
cycl
glycoconjug
synthesi
dealt
briefli
carbohydr
dglc
glucosamin
gicn
inhibit
synthesi
lipidlink
oligosaccharid
schwarz
datema
rasmussen
mode
action
differ
howev
see
point
sugar
analog
specif
inhibitor
dolichol
pathway
howev
condit
establish
experiment
sugar
analog
specif
inhibit
protein
glycosyl
metabol
pathway
schwarz
datema
exert
inhibit
dolichol
cycl
sugar
analog
metabol
notabl
except
glucosamin
metabol
sugar
analog
may
differ
differ
cell
anticellular
antivir
effect
lack
thereof
may
celltyp
depend
possibl
well
phosphoryl
enzym
glycolyt
pathway
scholtissek
sever
metabolit
sugar
found
cell
tabl
metabol
profil
proport
metabolit
celltyp
depend
decreas
nucleotid
pool
found
infect
cell
treat
sugar
analog
certain
condit
may
lead
decreas
viral
rna
protein
synthesi
scholtissek
keppler
et
al
protein
howev
still
affect
nucleotid
pool
imbal
prevent
discuss
relat
topic
see
scholtissek
inhibit
protein
glycosyl
dglc
correl
format
gdpdglc
schmidt
et
al
besid
gdpdgic
udpdglc
found
cell
treat
dglc
schmidt
et
al
result
anticip
dglc
analog
mannos
glucos
howev
also
least
yeast
chick
embryo
cell
metabol
udpand
gdpderiv
schwarz
datema
yeast
mammalian
cell
yield
grier
rasmussen
format
nucleotid
ester
dglc
decreas
pool
size
physiolog
nucleotid
sugar
gdpman
udpglcnac
schmidt
et
al
schwarz
et
al
datema
et
al
diminu
pool
size
udpglc
occasion
observ
lead
inhibit
protein
glycosyl
schwarz
datema
koch
et
al
rather
guanosin
diphosph
uridin
diphosph
ester
dglc
datema
schwarz
datema
et
al
datema
et
al
inhibit
certain
step
dolichol
pathway
sever
studi
subsequ
shown
inhibit
caus
guanosin
diphosph
ester
sugar
analog
dglc
possibl
also
strongli
contribut
inhibit
glycosyl
inhibit
caus
uridin
diphosph
ester
expect
sinc
mannos
prevent
antiinfluenza
viru
effect
dglc
effect
glucos
kaluza
et
al
schmidt
et
al
antivir
effect
fact
caus
inhibit
viral
protein
glycosyl
due
block
assembl
glcnac
datema
schwarz
chemic
synthesi
udpdgic
gdpdgic
made
possibl
studi
detail
mechan
inhibit
protein
glycosyl
see
tabl
cellfre
system
format
glcpdol
manpdol
glcnac
eppdol
endogen
dolp
exogen
sugar
nucleotid
inhibit
gdpdgic
trap
dolp
dglcpdol
respect
mcdowel
et
al
letoublon
et
al
assembl
lipidlink
oligosaccharid
inhibitori
condit
dolichol
cycl
dglc
dglclp
udpdgic
gdpdglc
acid
dglcdglcpdol
udpdglc
gdpdglc
dglcpdol
glcnac
udpgicnac
gicn
gicn
isol
intact
cell
occurr
presum
presenc
gdpdgic
datema
schwarz
mcdowel
et
al
howev
inhibit
due
interfer
trisaccharidelipid
format
reaction
b
fig
thu
dgic
glcnac
form
gicnac
gdpdgic
trisaccharid
lipid
deadend
assembl
accumul
similar
situat
appli
dgicman
gicnac
fig
fact
small
lipidlink
oligosaccharid
contain
dglc
found
ceil
treat
dglc
transfer
protein
obvious
gdpdgic
altern
substrat
mannosyltransferas
requir
gdpman
resist
toward
inhibit
glycosyl
dglc
therefor
obtain
increas
pool
gdpman
rel
gdpdgic
shown
dglcresist
bhk
celllin
schwarz
et
al
decreas
pool
size
gdpman
caus
inhibitor
impdehydrogenas
tiazofurin
mycophenol
acid
lead
decreas
format
lipidlink
oligosaccharid
sokoloski
sartorelli
incorpor
dolichol
diphosphatelink
trior
tetrasaccharid
instead
inhibit
format
man
gicnac
glcnac
gdpman
fig
like
inhibit
mannosyl
transferas
strongli
contribut
inhibit
lipidlink
oligosaccharid
assembl
intact
ceil
inhibit
protein
glycosyl
probabl
also
due
inhibit
synthesi
lipidlink
oligosaccharid
clear
caus
inhibit
inhibit
cellfre
system
incorpor
man
gdpman
lipidlink
oligosaccharid
inhibit
synthesi
glcpdol
manpdol
glcnac
interfer
assembl
dolichol
diphosphatelink
oligosaccharid
cellfre
system
furthermor
transfer
dolichol
phosphat
datema
et
al
result
surpris
cell
treat
format
gicpdol
manpdol
glcnac
inhibit
inhibit
glcpdol
format
may
caus
decreas
pool
size
udpgic
effect
see
howev
pool
gdpman
udpglcnac
decreas
cell
deplet
dolp
inhibit
transfer
glc
man
preform
dolp
deriv
incorpor
lipidlink
oligosaccharid
also
energi
charg
cell
decreas
inhibit
manpdol
format
affect
upon
incub
cell
way
dilemma
ie
sourc
inhibit
manpdol
lipidlink
oligosaccharid
format
cell
provid
find
block
format
retinolphosph
mannos
gdpman
exogen
retinol
phosphat
rat
liver
microsom
evid
see
p
suggest
prove
role
retinol
phosphat
format
manpdol
howev
could
shown
inhibit
format
retinolphosph
mannos
lead
inhibit
manpdol
format
thu
mode
action
satisfactorili
account
udpdglc
inhibit
synthesi
glcpdol
therefor
probabl
glucosyl
mang
glcnac
ppdol
enzym
dolichol
phosphat
udpglc
glucosyl
transferas
also
inhibit
datema
et
al
mcdowel
et
al
none
uridin
diphosph
ester
act
altern
substrat
enzym
tabl
fact
turn
throughout
eukaryot
investig
yeast
algal
chick
hamster
cell
group
glc
udpgic
crucial
activ
glucosyl
transferas
wherea
group
man
gdpman
essenti
mannosyl
transferas
schwarz
datema
mcdowel
et
al
datema
et
al
inhibit
gicpdol
format
uridin
diphosph
ester
sugar
analog
dglc
probabl
contribut
inhibit
protein
glycosyl
chick
cell
treat
sugar
analog
one
reason
major
block
caus
sugar
analog
occur
involv
gicpdol
anoth
reason
cell
appear
larg
pool
gicpdol
likewis
incorpor
dglc
possibl
dglcpdol
glcnac
instead
glc
man
see
fig
observ
cellfre
system
might
contribut
inhibit
protein
glycosyl
intact
cell
rather
dglc
earlyact
inhibitor
presenc
concentr
inhibit
influenza
viru
replic
viral
glycoprotein
glycosyl
small
lipidlink
oligosaccharid
transfer
protein
schwarz
datema
appli
glycosyl
influenza
viral
hemagglutinin
infect
cell
still
occur
probabl
via
gicnac
datema
et
al
synthesi
requir
manpdol
see
fig
glucos
analog
glucosamin
glcn
caus
sever
metabol
effect
chang
utp
atp
pool
scholtissek
decreas
rate
glycolysi
inhibit
protein
glycosyl
induct
chang
endomembran
system
format
excess
amount
udpglcnac
udpgalnac
schwarz
datema
koch
et
al
krug
et
al
keppler
et
al
effect
consequ
effect
effect
relat
glucosamin
cytotox
antivir
effect
certainli
uridyl
trap
lead
inhibit
rna
synthesi
may
caus
inhibit
viru
replic
howev
glucosecontain
media
inhibit
viral
rna
synthesi
occur
scholtissek
glucosamin
antivir
effect
condit
caus
inhibit
protein
glycosyl
due
interfer
oligosaccharidelipid
assembl
datema
schwarz
inhibit
oligosaccharidelipid
assembl
glucosamin
rapidli
revers
caus
amino
sugar
koch
et
al
prevent
assembl
lipidlink
oligosaccharid
datema
schwarz
give
rise
nonor
underglycosyl
glycoprotein
depend
concentr
drug
horisberg
et
al
also
locat
block
oligosaccharid
assembl
concentrationdepend
differ
intermedi
assembl
isol
cell
treat
differ
concentr
glcn
inhibit
oligosaccharidelipid
synthesi
glcn
increas
cell
treat
addit
local
anaesthet
lidocain
procain
interest
membraneact
drug
also
potenti
cytotox
amino
sugar
due
modif
membran
ultrastructur
friedman
skehan
effect
rapid
inhibit
protein
glycosyl
morin
et
al
howev
clear
whether
membran
chang
rapidli
revers
inhibit
protein
glycosyl
one
studi
show
ultrastructur
alter
caus
glcn
need
lead
inhibit
protein
glycosyl
morin
et
al
gicn
inhibit
oligosaccharidelipid
synthesi
crude
cellfre
system
unless
membran
fraction
prepar
buffer
contain
gicn
assembl
block
level
glcnac
product
also
found
accumul
cell
treat
high
concentratio
glucosamin
pan
elbein
remain
establish
whether
compon
oligosaccharidelipid
pathway
make
gi
mang
glcnac
gdpman
manpdol
gicpdol
present
glcntreat
cell
whether
concentr
decreas
fact
date
evid
avail
indic
prime
target
glcninhibit
dolichol
pathway
reason
multitud
biolog
effect
amin
structureact
relationship
amino
sugar
antivir
agent
lack
indic
earlier
p
biosynthesi
lipidlink
oligosaccharid
cellfre
system
necessarili
occur
via
orderli
sequenti
addit
mannos
residu
minor
amount
certain
isom
could
identifi
possibl
one
isom
heptasaccharidelipid
man
gicnac
accumul
cell
treat
mannosamin
pan
elbein
heptasaccharid
lipid
convent
intermedi
dolichol
pathway
structur
fig
probabl
structur
similar
ident
mansglcnac
z
found
intermedi
process
pathway
ii
fig
sugar
nucleotid
pool
decreas
mannosamin
suggest
amin
probabl
metabol
inhibit
mannosyl
transferas
interest
furthermor
observ
protein
still
glycosyl
presenc
mannosamin
assum
synthesi
glucosyl
lipidlink
intermedi
total
block
result
addit
evid
truncat
oligosaccharid
transfer
lipid
protein
intact
cell
interest
question
context
whether
truncat
oligosaccharid
accept
protein
whether
certain
protein
accept
oligosaccharid
whether
protein
accept
oligosaccharid
certain
condit
exampl
concomit
decreas
rate
intracellular
transport
nevertheless
amino
sugar
may
exert
biolog
effect
interf
protein
glycosyl
thu
inhibit
glucosidas
therefor
affect
glycoprotein
process
see
section
yet
effect
specif
toward
inhibit
glycoprotein
process
also
inhibit
format
dolichollink
oligosaccharid
inhibit
oligosaccharidelipid
format
elimin
inhibit
glucosidas
maintain
compound
nmethyl
romero
et
al
tunicamycin
ii
fig
repres
famili
nucleosid
antibiot
streptovirudin
mycospocidin
also
belong
tamura
tunicamycin
isol
character
tamura
cowork
tamura
compos
nucleosid
uracil
claminodeoxi
dialdos
tunicamin
substitut
anomer
carbon
gicnac
amino
group
longchain
fatti
acid
elbein
mixtur
homologu
make
tunicamycin
differ
structur
fatti
acid
compon
total
synthesi
tunicamycin
recent
achiev
suami
et
al
tunicamycin
udpgicnac
analog
inhibit
enzym
transloc
deriv
thereof
uridin
diphosph
ester
polyprenol
phosphat
elbein
notabl
tunicamycin
inhibit
first
step
dolichol
pathway
udpglcnacdolpgicnacppdoiump
tkacz
lampen
takatsuki
et
al
lehl
tanner
tunicamycinrel
antibiot
potent
rather
specif
inhibitor
format
glcnacppdol
elbein
et
al
therefor
lipidlink
oligosaccharid
format
anim
plant
fungal
system
specif
cours
ii
absolut
reaction
shown
inhibit
rather
high
concentr
antibiot
addit
tunicamycin
treatment
cell
caus
increas
udpglcnac
pool
alter
ultrastructur
endoplasm
reticulum
nuclear
membran
morin
et
al
howev
antivir
anticellular
cytotox
effect
tunicamycin
certainli
primarili
due
inhibit
protein
glycosyl
interest
tunicamycin
inhibit
format
gicnac
udpglcnac
gicnacppdol
similar
reaction
involv
transfer
gicnac
lehl
tanner
ward
et
al
carrasco
vazquez
fact
studi
mechan
action
tunicamycin
streptovirudin
indic
compound
bind
tightli
glcnacip
transferas
k
tunicamycin
x
bind
revers
difficulti
high
substrat
concentr
keller
et
al
heifetz
et
al
major
tunicamycin
homologu
differ
biolog
properti
exampl
differ
amount
drug
need
inhibit
protein
glycosyl
cell
found
duksin
et
al
homologu
contain
satur
fattyacid
side
chain
one
activ
inhibitor
glycosyl
cell
drug
also
show
high
select
toxic
toward
transform
cell
duksin
et
al
seiberg
duksin
possibl
differ
activ
homologu
relat
differ
membran
penetr
whether
plasma
membran
membran
endoplasm
reticulum
contain
glcnacip
transferas
eren
duksin
given
mice
tunicamycin
casero
et
al
close
rel
streptovirudin
tonew
et
al
therapeut
effect
infect
caus
trypanosoma
resp
influenza
howev
drug
toxic
exampl
impair
postnat
develop
cerebellum
rat
koshaka
et
al
sever
antibiot
block
step
dolichol
pathway
test
cellfre
system
amphomycin
diumycin
showdomycin
bacitracin
tsushimycin
mode
action
partial
elucid
review
see
inhibitor
synthesi
dolichol
phosphat
also
report
schwarz
datema
hem
drug
address
extens
use
virusinfect
cell
howev
drug
use
experiment
tool
cellfre
system
dissect
certain
step
dolichol
pathway
see
schwarz
datema
elbein
also
sever
sugar
analog
mention
usual
simpl
fuorin
carbohydr
deoxysugar
amino
sugar
interfer
glycoconjug
biosynthesi
necessarili
dolichol
pathway
antivir
effect
systemat
investig
review
see
bernacki
korytnyk
schwarz
datema
reutter
bauer
synthet
analog
sugar
nucleotid
modifi
nucleosid
portion
diphosphatebridg
receiv
surprisingli
littl
attent
inhibitor
glycosyl
transferas
eukaryot
cell
enzym
prokaryot
cell
see
shibaev
thu
littl
anyth
known
structur
element
base
ribosemoieti
requir
interact
glycosyl
transferas
see
howev
bernacki
korytnyk
exert
inhibit
intact
cell
sugarnucleotid
analog
cross
plasma
membran
inhibit
enzym
involv
termin
glycosyl
golgi
membran
udpglucos
analog
iii
fig
may
least
former
properti
inhibit
glycosyl
viral
glycoprotein
camarasa
et
al
although
inhibitor
virusspecif
despit
claim
contrari
synthet
approach
novel
glycosyl
inhibitor
interest
metabol
lead
format
fluorouridin
nucleotid
sugar
fudphexos
fudphexosamin
mammalian
tumour
see
weckbeck
keppler
literatur
cite
therein
hepatoma
cell
cellfre
system
metabol
pattern
fudpsugar
observ
analog
udpsugar
addit
fudpgic
fudpgicnac
serv
substrat
format
gicpdol
gicnac
liver
cell
treat
galactosamin
fudpgicn
form
holsteg
et
al
lipidlink
saccharid
format
block
possibl
format
gicnpdol
fraudul
sugar
nucleotid
compet
format
physiolog
dolichollink
saccharid
mcdowel
et
al
experi
underlin
potenti
nucleosid
nucleotid
analog
glycosyl
inhibitor
bi
amidinohydrazon
deriv
name
ihbenz
f
dionebisamidinohydrazon
structur
fig
select
antiherp
activ
cavrini
et
al
block
glycosyl
infect
cell
uninfect
cell
sindbi
virusor
paramyxovirusinfect
cell
serafinicessi
campadellifium
drug
presum
prevent
attach
highmannos
oligosaccharid
virusspecifi
glycoprotein
known
exampl
virusspecif
glycosyl
inhibitor
subsequ
genet
studi
confirm
virusspecif
block
sinc
mutant
resist
drug
could
isol
tognon
et
al
mode
action
still
obscur
exclud
drug
interfer
nucleotid
sugar
nucleotid
metabol
thu
interf
assembl
theaipidlink
oligosaccharid
inde
hsv
code
number
enzym
involv
nucleotid
metabol
metabol
effect
galactosamin
see
decker
keppler
keppler
et
al
two
potenti
chemotherapeut
agent
name
anthracyclin
aclacinomycin
ii
fig
marcellomycin
induc
tumor
cell
differenti
inhibit
protein
glycosyl
presum
inhibit
format
dolichollink
oligosaccharid
morin
sartorelli
block
pathway
exert
anthracyclin
known
also
appli
anoth
glycosyl
inhibitor
atropin
alarcon
et
al
amino
acid
analog
antagonist
lglutamin
inhibit
protein
glycosyl
inhibit
convers
dfructos
glucosamin
green
pratt
hand
threonin
analog
flhydroxynorvalin
incorpor
protein
instead
threonin
inhibit
glycosyl
acceptor
asnresidu
hortin
boim
like
transfer
oligosaccharid
dolichollink
oligosaccharid
protein
steric
hinder
flhydroxynorvalin
substitut
thr
tripeptid
sequenc
asnxthr
hortin
noim
docherti
aronson
cellfre
system
glycosyl
coupl
protein
synthesi
dlthreoflfluoroasparagin
inhibit
asnlink
glycosyl
follow
incorpor
analog
protein
hortin
et
al
amino
acid
analog
flhydroxynorvalin
dlthreofluoroasparagin
therefor
seem
prevent
protein
glycosyl
without
block
assembl
lipidlink
oligosaccharid
extens
work
shown
cellfre
system
hexapeptid
argasnglyepoxyethylglycinealavalom
structur
iii
fig
could
inactiv
oligosaccharid
transferas
baus
inhibit
activesitedirect
occur
catalysi
possibl
via
suicid
mechan
follow
transfer
oligosaccharid
dolichol
diphosph
protein
oligosaccharid
process
see
section
extent
process
differ
differ
protein
differ
oligosaccharid
chain
particular
protein
pollack
atkinson
consequ
process
particular
protein
differ
time
point
life
equip
differ
oligosaccharid
process
pathway
allow
gener
divers
oligosaccharid
structur
time
turn
allow
differ
function
particular
side
chain
differ
time
life
glycoprotein
see
section
thu
inhibit
glycoprotein
process
result
glycoprotein
immatur
form
nlink
oligosaccharid
earli
step
process
pathway
depend
activ
glucosidas
mannosidas
inhibitor
enzym
test
inhibit
glycoprotein
process
process
oligosaccharid
glycoprotein
occur
differ
intracellular
compart
section
disrupt
intracellular
traffic
ionophor
exampl
lead
inhibit
process
later
step
process
pathway
requir
glycosyl
transferas
inhibitor
glycosyl
transferas
therefor
potenti
process
inhibitor
section
address
mainli
commonli
use
process
inhibitor
ie
glycosidas
inhibitor
inhibitor
dealt
briefli
note
mutant
cell
line
defect
defici
process
enzym
use
extens
mean
interfer
glycoprotein
process
properti
mutant
reader
refer
review
stanley
also
viral
mutant
alter
intracellular
transport
cell
mutant
affect
process
pathway
describ
valid
membran
protein
viral
envelop
protein
belong
protein
lysosom
protein
protein
yeast
subject
process
pathway
differ
particular
step
one
describ
review
see
kornfeld
kornfeld
secretori
pathway
cell
use
equip
glycoprotein
alter
oligosaccharid
structur
tartakoff
glycosidas
inhibitor
interfer
glycoprotein
process
inhibitor
glucosidas
occur
endoplasm
reticulum
golgi
system
elbein
structur
point
view
inhibitor
classifi
see
fig
sugar
analog
bromoconduritol
nojirimycin
nmethylldeoxynojirimycin
mannoldeoxynojirimycin
b
indolizidin
alkaloid
swainsonin
castanospermin
substanc
obtain
chemic
synthesi
myoinositol
activesit
direct
coval
inhibitor
tglucosidas
legler
lotz
legler
reaction
bromoconduritol
yeast
ctglucosidas
appear
histidin
residu
modifi
indic
reaction
goe
via
epoxid
form
activ
site
dehydrobromin
inhibitor
legler
lotz
legler
bromoconduritol
inhibit
releas
glucos
oligosaccharid
ratliv
glucosidas
prepar
accumul
henc
presenc
bromoconduritol
trim
last
glucos
inhibit
datema
et
al
intact
cell
bromoconduritol
inhibit
synthesi
nlink
complextyp
oligosaccharid
chain
high
mannos
oligosaccharid
composit
glclmantgglcnac
accumul
thu
bromoconduritol
inhibit
synthesi
complextyp
oligosaccharid
inhibit
releas
innermost
glucos
residu
glcnac
precursor
complextyp
hybridtyp
highmannos
oligosaccharid
datema
et
al
data
interpret
drug
inhibit
glucosidas
ii
cellfre
system
intact
cell
although
oligosaccharid
one
glc
residu
rather
two
glc
residc
accufnul
presenc
bromoconduritol
cf
fig
nigeros
glcl
competit
inhibitor
enzym
saunier
et
al
activ
site
may
contain
least
two
glucosebind
site
bromoconduritol
therefor
presum
interfer
bind
oligosaccharid
releas
glucos
group
catalyt
site
enzym
sinc
bromoconduritol
complet
inhibit
releas
glc
glcmanxglcnacr
datema
et
al
substrat
appar
bind
bromoconduritolmodifi
enzym
result
also
indic
complet
glucos
trim
necessari
mannosetrim
sinc
oligosaccharid
bromoconduritoltr
cell
composit
glclmanx
glcnac
x
see
fig
observ
previous
kornfeld
et
al
also
studi
glucosidas
inhibitor
see
show
intact
cell
mannos
trim
occur
despit
fact
glucosetrim
compelet
inhibit
antibiot
obtain
streptomyc
speci
ishida
et
al
first
found
natur
inouy
et
al
glucoseanalog
nitrogen
atom
instead
oxygen
pyranos
ring
nojirimycin
inhibit
glucosidas
nonmammalian
origin
potent
inhibitor
latter
niwa
et
al
rees
et
al
amino
sugar
competit
inhibitor
synthesi
biantennari
complextyp
nlink
oligosaccharid
step
pathway
inhibit
process
inhibitor
abbrevi
mdnnmethylldeoxynojirimycin
cascastanospermin
mannoldeoxynojirimycin
iiglcnac
oman
x
glc
ogal
neuac
note
inhibit
mdn
ca
intact
cell
lead
accumul
also
intact
cell
bromoconduritol
accumul
glcimangglcnac
also
glctmantsglcnac
form
small
intestin
sucras
hanozet
et
al
strongli
inhibit
purifi
lysosom
glucosidas
human
liver
sourc
enzym
whole
human
liver
homogen
nojirimycin
specif
inhibit
hydrolysi
alink
glucos
affect
releas
fllink
glucos
chamber
et
al
thu
appear
mammalian
system
glucosidas
strongli
inhibit
flglucosidas
use
microsom
glucosidas
prepar
rat
liver
substrat
nojirimycin
inhibit
glucos
releas
complet
calf
liver
use
sourc
enzym
hydrolysi
also
inhibit
higher
concentr
inhibitor
inhibit
hettkamp
et
al
thu
nojirimycin
potent
inhibitor
process
glucosidas
intact
cell
mm
nojirimycin
caus
drastic
chang
electrophoret
mobil
igd
igm
hybridoma
cell
base
chang
comparison
chang
obtain
tunicamycintr
cell
suggest
presenc
nojirimycin
glycoprotein
contain
one
possibl
two
nacetyl
glucosamin
residu
synthes
peyriera
et
al
clearli
nojirimycin
act
glucosidaseinhibitor
condit
influenza
fowl
plagu
virusinfect
chick
embryo
cell
nojirimycin
strongli
inhibit
incorpor
mannos
lipidlink
oligosaccharid
glycoprotein
henc
nojirimycin
specif
inhibitor
process
condit
use
result
clearli
demonstr
studi
necessari
determin
mode
action
assess
use
nojirimycin
trim
inhibitor
obtain
reduct
nojirimycin
catalyt
inouy
et
al
later
isol
sever
strain
bacillu
mulberri
tree
leav
strain
streptomyc
also
synthes
chemic
via
sever
rout
review
see
truscheit
et
al
see
also
bernota
ganem
refer
cite
therein
like
parent
compound
potent
inhibitor
sever
intestin
glucosidas
sucras
maltas
isomaltas
glucoamylas
schmidt
et
al
contrari
nojirimycin
weak
inhibitor
flglucosidas
nonmammalian
origin
niwa
et
al
legler
jfilich
nojirimycin
ldeoxynojirimycin
fulli
competit
inhibitor
small
intestin
sucras
studi
carri
enzym
hanozet
et
al
suggest
nojirimycin
bound
activ
center
enzym
nonproton
form
subsequ
proton
thu
mimick
transit
state
form
catalysi
also
potent
inhibitor
trim
glucosidas
enzym
yeast
inhibit
observ
glucosidas
glucosidas
ii
saunier
et
al
revers
appear
hold
glucosidas
calf
liver
microsom
inhibit
glucosidas
requir
tam
wherea
drug
inhibit
glucosidas
ii
extent
hettkamp
et
al
inhibit
either
glucosidas
calf
pancrea
microsom
observ
saunier
et
al
releas
glucos
gi
mangglcnac
rat
liver
microsom
prepar
abolish
intact
cell
inhibit
synthesi
nlink
complextyp
oligosaccharid
saunier
et
al
gross
et
al
highmannos
oligosaccharid
composit
accumul
romero
et
al
mixtur
consist
oligosaccharid
contain
three
glucos
residu
thu
intact
cell
exert
action
trim
glucosidas
preferenti
inhibit
glucosidas
ii
report
biolog
effect
necessarili
relat
inhibit
trim
glucosidas
could
due
part
gener
inhibit
synthesi
lipidlink
oligosaccharid
specif
inhibit
gicnac
seen
intestin
epitheli
cell
romero
et
al
intestin
ceil
inhibit
glcnac
abolish
inhibitor
ad
medium
contain
gl
instead
glucos
clearli
conclus
deriv
studi
regard
role
carbohydr
glycoprotein
assess
care
light
multipl
effect
sugar
analog
romero
et
al
obtain
methyl
murai
et
al
presenc
methyl
group
nitrogen
atom
two
import
biolog
effect
first
mention
nojirimycin
certain
condit
ldeoxynojirimycin
inhibit
synthesi
lipidlink
oligosaccharid
romero
et
al
inhibit
observ
nmethylldeoxynojirimycintr
cell
romero
et
al
second
nmethylldeoxynojirimycin
potent
inhibitor
process
glucosidas
cellfre
system
romero
et
al
hettkamp
et
al
saunier
b
jelinekkelli
herscov
unpublish
work
intact
cell
strongli
inhibit
synthesi
nlink
complextyp
oligosaccharid
mainli
high
mannos
oligosaccharideswith
composit
glcamantq
glcnac
accumul
romero
et
al
romero
herscov
direct
comparison
effect
ldeoxynojirimycin
glycoprotein
biosynthesi
rat
intestin
epitheli
cell
cultur
indic
mm
nmethyl
deriv
necessari
maxim
inhibit
synthesi
complextyp
oligosaccharid
wherea
requir
obtain
effect
furthermor
found
highmannos
oligosaccharid
form
presenc
nmethylldeoxynojirimycin
contain
glucos
residu
compar
correspond
oligosaccharid
cell
romero
et
al
henc
intact
cell
nmethylldeoxynojirimycin
inhibit
complextyp
oligosaccharid
synthesi
inhibit
mainli
action
glucosidas
alkaloid
isol
seed
castanospermum
austral
hohenschutz
et
al
l
chemic
synthesi
dglucos
recent
report
bernota
granem
seed
eaten
hors
cattl
caus
sever
gastrointestin
irrit
sometim
death
hohenschutz
et
al
studi
done
vivo
inject
castanospermin
rat
indic
activ
glycosidas
inhibit
neutral
acid
ctglucosidas
liver
brain
kidney
spleen
activ
other
unchang
liver
flgalactosidas
elev
liver
flnacetylhexosaminidas
saul
et
al
castanospermin
potent
inhibitor
flglucosidas
flglucocerebrosidas
lysosom
glucosidas
inhibit
flglucosidas
mix
type
bind
castanospermin
enzym
appear
revers
cell
treat
castanospermin
glycoprotein
equip
highmannos
oligosaccharid
contain
three
glucos
residu
accumul
pan
et
al
fact
biolog
effect
far
report
castanospermin
nmethylldeoxynojirimycin
similar
exampl
viral
glycoprotein
studi
appear
metabol
stabl
synthes
presenc
drug
proteolyt
cleavag
polyprotein
precursor
sindbi
viru
prevent
either
drug
virusinfect
bhk
cell
see
also
section
studi
carri
human
hepatoma
cell
show
secret
certain
glycoprotein
eg
cqantitrypsin
ceruloplasmin
markedli
decreas
drug
secret
antithrombin
iii
slightli
affect
sasak
et
al
similar
differenti
effect
observ
secret
glycosidas
aspergillusfumigatu
known
decreas
activ
measur
cultur
media
fungu
inhibit
secret
glycosidas
due
secret
less
activ
enzym
elbein
et
al
castanospermin
inhibit
receptormedi
uptak
mannosetermin
glycoprotein
macrophag
chung
et
al
see
p
possibl
explan
pyrrolidin
alkaloid
analog
fldfructofuranos
isol
leav
derri
elliptica
welter
et
al
seed
lonchocarpu
sericeu
evan
et
al
recent
chemic
synthesi
report
card
hitz
dmdp
potent
inhibitor
tand
flglucosidas
evan
et
al
card
hitz
concentr
requir
produc
inhibit
gand
flglucosidas
activ
time
time
lower
respect
evan
et
al
inhibit
appar
competit
case
depend
upon
ph
manner
suggest
nonproton
form
dmdp
activ
inhibitor
card
hitz
influenza
virusinfect
mdck
cell
addit
dmdp
inhibit
synthesi
nlink
complextyp
oligosaccharid
analysi
accumul
product
show
presenc
highmannos
oligosaccharid
composit
glcnac
indic
dmdp
inhibit
trim
glucosidas
elbein
et
al
intestin
epitheli
cell
cultur
dmdp
also
inhibit
synthesi
nlink
complextyp
oligosaccharid
mixtur
highmannos
type
oligosaccharid
found
glcnac
account
label
oligosaccharid
also
small
increas
glucosyl
oligosaccharid
rel
untreat
cell
appar
primari
effect
dmdp
complextyp
oligosaccharid
synthesi
cell
result
inhibit
glucosidas
romero
et
al
reason
differ
mode
action
dmdp
influenza
virusinfect
mdck
cell
uninfect
intestin
epitheli
cell
unclear
remain
elucid
indolizidin
alkaloid
isol
plant
swainsona
canescen
coleg
et
al
spot
locowe
astragalu
lentiginosu
molyneux
jame
well
fungu
rhil
octonia
legurninicola
schneider
et
al
chemic
synthesi
dglucos
ali
et
al
dmannos
fleet
et
al
report
cellfre
system
swainsonin
revers
activ
sitedirect
inhibitor
lysosom
mannosidas
dorl
et
al
also
inhibit
golgi
ctmannosidas
ii
tulsiani
et
al
reaction
revers
lysosom
enzym
inhibitioni
competit
concentr
test
tm
tulsiani
et
al
swaisonin
administ
rat
pig
activ
golgi
mannosidas
ii
inhibit
expect
contrari
expect
increas
tissu
level
lysosom
mannosidas
occur
tulsiani
touster
tulsiani
et
al
swainsonin
consid
agent
respons
diseas
manifest
graze
livestock
resembl
hereditari
lysosom
ctmannosidosi
eg
induc
lysosomallik
pleomorph
vacuol
cell
caus
accumul
free
oligosaccharid
lead
certain
neurolog
disord
coleg
et
al
dorl
et
al
molyneux
jame
novikoff
et
al
quantit
analysi
oligosaccharid
excret
urin
locoweedintox
sheep
may
use
method
detect
diseas
earli
stage
daniel
et
al
addit
induc
phenocopi
genet
mannosidosi
swainsonin
isol
fungu
metarhizium
anisoplia
act
immunomodul
vivo
kino
et
al
see
also
section
whether
latter
effect
due
compound
inhibit
glycoprotein
process
known
intact
cell
swainsonin
inhibit
synthesi
complextyp
oligosaccharid
elbein
et
al
hybridtyp
oligosaccharid
form
instead
tulsiani
touster
mode
action
predict
studi
cellfre
system
demonstr
drug
prevent
biosynthesi
complextyp
oligosaccharid
inhibit
golgi
mannosidas
ii
tulsiani
et
al
see
fig
presenc
swainsonin
viral
glycoprotein
equip
hybrid
instead
complextyp
oligosaccharid
viru
particl
releas
inhibit
system
far
studi
see
section
furthermor
secret
tantitrypsin
gross
et
al
fibronectin
arumugham
tanzer
aantichymotrypsin
transferrin
complement
lodish
kong
igd
igm
peyriera
et
al
affect
drug
fact
human
hepatoma
cell
swainsonin
acceler
intracellular
transport
secret
glycoprotein
transferrin
ceruloplasmin
rantitrypsin
secret
nonglycoprotein
albumin
see
yeo
et
al
discuss
phenomenon
line
cell
surfac
express
vfm
nichol
et
al
hadwig
et
al
erbb
schmidt
et
al
oncogen
product
see
also
section
histocompat
antigen
hlaa
b
c
hladr
peyriera
et
al
insulin
insulinlik
growth
factor
receptor
duronio
et
al
normal
swainsoninetr
cell
howev
swainsonin
inhibit
receptormedi
uptak
degrad
macrophag
mannosyloligosaccharid
arumugham
tanzer
mannosetermin
glycoprotein
chung
et
al
suggest
inhibit
receptormedi
uptak
mannosetermin
glycoprotein
caus
perman
occup
receptor
mannosetermin
membran
glycoprotein
accumul
presenc
swainsonin
chung
et
al
explan
also
propos
similar
effect
uptak
system
observ
process
inhibit
castanospermin
dmm
mannos
analog
natur
occur
product
present
seed
legum
lonchocarpu
sericeu
lonchocarpu
costaricensi
first
isol
fellow
et
al
subsequ
chemic
synthes
sever
method
kinast
schedel
see
also
bernota
ganem
refer
cite
therein
inhibit
ctand
fldmannosidas
time
better
reaction
product
mannos
inhibit
less
mark
inhibit
glucosidas
nojirimycin
legler
jiilich
cellfre
system
yeast
dmm
specif
inhibit
enzym
remov
mannos
mangglcnac
effect
mannosidaseact
jelinekkelli
et
al
noncompetit
inhibitor
rat
liver
golgi
ctmannosidas
enzym
rather
sensit
drug
inhibit
occur
dmm
affect
slightli
lysosom
mannosidas
inhibit
rough
endoplasm
reticulum
solubl
tmannosidas
bischoff
kornfeld
observ
mannos
analog
mannosidas
inhibitor
suggest
reaction
mechan
trim
glucosidas
mannosidas
similar
may
involv
cation
reaction
intermedi
lalrgeri
et
al
fuhrmann
et
al
intact
cell
prevent
synthesi
nlink
complextyp
oligosaccharid
caus
accumul
oligosaccharid
composit
manvgglcnac
high
proport
mangglcnac
fuhrmann
et
al
elbein
et
al
bosch
et
al
romero
et
al
romero
herscov
henc
intact
cell
dmm
act
primarili
inhibit
specif
golgi
mannosidas
activ
mention
nmethylldeoxynojirimycin
better
inhibitor
glucosidas
nmethyl
hand
potent
inhibitor
golgi
mannosidas
intact
cell
nonmethyl
form
bosch
et
al
inhibit
golgi
tmannosidas
activ
result
synthesi
glycoprotein
equip
nonglucosyl
high
mannos
oligosaccharid
affect
secret
igd
igm
hybridoma
cell
fuhrmann
et
al
atacid
glycoprotein
rantitrypsin
primari
cultur
rat
hepatocyt
gross
et
al
cell
surfac
express
human
class
histocompat
antigen
burk
et
al
effect
cellspecif
exampl
human
hepatoma
cell
process
intracellulari
retain
cathepsin
retard
fraction
secret
cathepsin
increas
twofold
wherea
fibroblast
neither
segreg
matur
affect
nauerth
et
al
similarli
biosynthesi
lipidlink
oligosaccharid
glycoprotein
strongli
inhibit
influenza
chick
embryo
cell
inhibit
mu
mdckcell
unless
high
concentr
use
inhibit
mannos
incorpor
glycoprotein
elbein
et
al
result
togeth
nauerth
et
al
show
dmm
caus
inhibit
incorpor
mannos
tricholoroacet
acidinsolubl
materi
fibroblast
suggest
need
caution
biolog
effect
obtain
dmm
could
relat
inhibit
golgi
mannosidas
analogu
furanos
sugar
synthes
chemic
benzyl
ctdmannopyranosid
fleet
et
al
effect
inhibitor
jack
bean
tmannosidas
swainsonin
palamarczyk
et
al
better
one
fleet
et
al
also
inhibit
lysosom
mannosidas
although
high
concentr
dim
requir
palamarczyk
et
al
inhibit
competit
enzym
pnitrophenyl
tdmannopyranosid
use
substrat
fleet
et
al
palamarczyk
et
al
natur
occur
pyrrolidin
alkaloid
dmdp
form
unproton
nitrogen
ring
furanos
analog
activ
inhibitor
card
hitz
palamarczyk
et
al
intact
cell
dim
inhibit
synthesi
complextyp
oligosaccharid
mainli
highmannos
oligosaccharid
composit
mang
glcnac
accumul
addit
small
proport
materi
endo
hsensit
resist
jack
bean
tmannosidas
suggest
latter
materi
might
repres
hybridtyp
oligosaccharid
henc
intact
cell
dim
act
inhibit
mannosidas
perhap
ii
far
less
effect
swainsonin
inhibit
synthesi
nlink
complex
oligosaccharid
palamarczyk
et
al
find
contrast
sharpli
inhibit
found
cellfre
system
fldglucopyranosylmethylpnitrophenyltriazen
fld
galactopyranosylmethylpnitrophenyltriazen
dmannopyranosylmethylpnitrophenyltriazen
inactiv
lysosom
flglucosidas
flgalactosidas
van
diggelen
et
al
ctmannosidas
docherti
et
al
respect
suicid
inhibitor
irrevers
activesit
direct
inhibitor
enzym
cultur
hepatocyt
incub
presenc
mm
dmannopyranosylmethylpnitrophenyltriazen
glycoprotein
equip
highmannos
oligosaccharid
glcnac
z
instead
nlink
complextyp
oligosaccharid
remain
determin
mannosidas
inhibit
triazen
follow
remov
drug
normal
cqacid
glycoprotein
synthesi
resum
hr
presum
due
synthesi
de
novo
mannosidas
analysi
glycoprotein
equip
highmannos
oligosaccharid
form
cell
treat
glucosidas
inhibitor
bromoconduritol
nmethylldeoxynojirimycin
castanospermin
dmdp
show
two
mannos
residu
remov
action
process
mannosidas
known
yet
trim
mannos
condit
caus
action
rough
endoplasm
reticulum
ctmannosidas
golgi
tmannosidas
combin
action
enzym
similar
effect
observ
presenc
golgi
mannosidas
inhibitor
condit
synthesi
nlink
complex
type
oligosaccharid
complet
inhibit
fuhrmann
et
al
elbein
et
al
romero
et
al
romero
herscov
like
therefor
remov
mannos
residu
observ
presenc
due
rough
endoplasm
reticulum
ctmannosidas
activ
bischoff
kornfeld
romero
et
al
inhibit
earli
step
process
nlink
oligosaccharid
action
glucosidas
inhibitor
effect
depend
part
particular
glycoprotein
cellular
system
studi
studi
effect
observ
see
also
section
kornfeld
kornfeld
hand
usual
inhibit
glycoprotein
transport
secret
observ
process
inhibit
late
step
name
inhibit
golgi
mannosidas
ii
swainsonin
howev
gener
concern
role
oligosaccharid
process
could
erron
see
section
fact
cellular
system
use
inhibitor
eg
ldeoxymannojirimycin
effect
clearli
unrel
inhibit
process
glycosidas
exampl
inhibit
glycoprotein
lipidlink
oligosaccharid
synthesi
suggest
cautiou
approach
use
substanc
summari
trim
inhibitor
valuabl
tool
studi
role
nlink
oligosaccharid
glycoprotein
provid
mode
action
determin
clearli
understood
inhibitor
use
ligand
purif
affin
chromatographi
process
glycosidas
hettkamp
et
al
schweden
et
al
thu
coupl
ahsepharos
use
purifi
calf
liver
mannosidas
capabl
remov
three
link
mannos
mang
glcnac
schweden
et
al
exist
endoplasm
reticulum
ctmannosidas
also
suggest
bischoff
et
al
enzym
respons
trim
oligosaccharid
glcnac
glcnac
inhibitor
also
proven
use
determin
intact
cell
structur
featur
requir
enzym
modifi
oligosaccharid
exampl
sulfat
influenza
viru
glycoprotein
occur
swainsoninetr
influenza
virusinfect
mdck
cell
absent
castanosperminetr
cell
thu
appear
sulfat
requir
previou
action
nacetylglucosaminyl
transferas
merkl
et
al
similar
requir
observ
fucosyl
transferas
add
lfucos
link
ct
innermost
nacetylglucosamin
residu
complextyp
oligosaccharid
hemagglutinin
influenza
viru
neither
glycoprotein
synthes
presenc
glucosidas
inhibitor
castanosperminc
dmdp
schwarz
elbein
form
presenc
golgi
inhibitor
fucos
hybrid
structur
synthes
swainsoninetr
cell
fucosyl
schwarz
elbein
number
sugar
analog
interfer
termin
glycosyl
reaction
certain
system
review
see
bernacki
korytnyk
schwarz
datema
reutter
bauer
corfield
schauer
see
also
schwartz
et
al
also
analog
sugar
nucleotid
exampl
analog
cmpneuac
block
termin
glycosyl
reaction
cf
bernacki
korytnyk
new
addit
list
sugar
nucleotid
analog
two
disaccharid
nucleosid
methoxycarbonyldglycerotdgalactooctapyranosyl
uridin
methoxycarbonyidglyceroctdgalactooctapyranosyl
inosin
kijimasuda
et
al
compound
competit
inhibitor
sialyltransferas
inosin
analog
rather
specif
inhibitor
sialyl
transfer
olink
oligosaccharid
catalyz
murin
lymphocyt
biolog
properti
inhibitor
termin
glycosyl
discuss
section
studi
role
oligosaccharid
glycoprotein
number
approach
use
inhibitor
prevent
attach
oligosaccharid
protein
inhibitor
prevent
glycoprotein
process
mutant
celllin
defect
enzym
glycosyl
pathway
chemic
enzymat
deglycosyl
prove
use
investig
role
nlink
oligosaccharid
viral
glycoprotein
clear
discuss
section
function
olink
oligosaccharid
less
well
studi
nlink
oligosaccharid
specif
inhibitor
olink
oligosaccharid
synthesi
avail
olink
oligosaccharid
recent
recogn
compon
viral
glycoprotein
role
nglycosyl
studi
numer
biolog
system
mainli
use
tunicamycin
lesser
extent
deoxyglucos
studi
review
sever
occas
schwarz
datema
elbein
olden
et
al
olden
et
al
kornfeld
kornfeld
von
figura
hasilik
attempt
made
repeat
instead
concentr
effect
inhibitor
glycosyl
glycoprotein
process
virusinfect
cell
interfer
protein
glycosyl
result
divers
biolog
effect
depend
celltyp
glycoprotein
investig
nevertheless
generalis
oligosaccharid
function
formul
viral
glycoprotein
oligosaccharid
need
play
role
protein
conform
metabol
stabil
viral
glycoprotein
proteolyt
process
polyprotein
precursor
viral
glycoprotein
intracellular
traffic
antigen
infect
cell
note
may
consequ
biolog
activ
glycoprotein
affect
interfer
glycosyl
olden
et
al
case
oligosaccharid
may
particip
directli
reaction
involv
oligosaccharideprotein
interact
receptor
recognit
cell
adhes
baenzig
glycoprotein
rna
virus
part
envelop
virus
envelop
deriv
infect
cell
membran
bud
mechan
wiley
viral
surfac
glycoprotein
inde
number
properti
common
cellular
membran
glycoprotein
insert
cellular
membran
transport
differ
subcellular
locat
cellular
transport
system
dunphi
rothman
wickner
lodish
addit
amino
acid
sequenc
membran
glycoprotein
rna
virus
share
number
common
featur
see
fig
membraneanchor
sequenc
uncharg
primarili
hydrophob
amino
acid
found
near
cterminu
ampl
evid
sequenc
span
membran
anchor
glycoprotein
specif
amino
acid
sequenc
found
hydrophob
stretch
hydrophob
stretch
serin
threoin
residu
occur
may
esterifi
fatti
acid
posttransl
schmidt
cterminu
small
hydrophil
sequenc
occur
cytoplasm
site
membran
toward
inner
core
viru
particl
domain
vari
size
wiley
dipeptid
el
glycoprotein
semliki
forest
viru
undecapeptid
hemagglutinin
fowl
plaqu
viru
lamino
acid
stretch
glycoprotein
semliki
forest
viru
hydrophil
domain
assum
play
role
viru
bud
wiley
garoff
et
al
interact
viral
nucleocapsid
matrix
protein
see
fig
anoth
stretch
primarili
hydrophob
amino
acid
occur
ntermin
part
socal
signal
leadersequ
found
secretoryand
membranebound
protein
protein
synthes
amino
termin
extens
least
eleven
uncharg
amino
acid
membranebound
polyribosom
leaderpeptid
specif
sequenc
requir
exist
direct
transmembran
transloc
nascent
chain
lumen
endoplasm
reticulum
process
ensur
compartiment
studi
detail
wickner
lodish
walter
et
al
perara
et
al
wherea
secretori
protein
appear
releas
lumen
endoplasm
reticulum
viral
membran
glycoprotein
remain
anchor
membran
via
hydrophob
ctermin
sequenc
usual
signal
peptid
remov
nascent
chain
signal
peptidas
influenza
neuraminidas
one
except
ctermin
anchor
probabl
stuck
membran
via
signal
sequenc
murphi
webster
amino
acid
sequenc
character
oligosaccharideattach
site
sequenc
involv
membranefus
activ
viral
glycoprotein
fig
envelop
glycoprotein
rna
virus
nglycosyl
cotransl
kornfeld
kornfeld
also
initi
oligosaccharid
trim
may
occur
membranebound
ribosom
shown
vesicular
stomat
viru
atkinson
lee
absenc
glycosyl
sequestr
nascent
viral
glycoprotein
cytoplasm
lumen
endoplasm
reticulum
prevent
garoff
schwarz
mechan
intracellular
transport
viral
glycoprotein
site
bud
host
cell
mechan
respons
compan
klenk
compan
dunphi
rothman
still
poorli
understood
see
section
rna
virus
bud
plasma
membran
certain
polar
epitheli
cell
influenza
parainfluenza
virus
matur
exclus
apic
surfac
vesicular
stomat
viru
certain
ctype
retrovirus
basolater
surfac
rodriguezboulan
sabbatini
roth
et
al
morrison
ward
specif
matur
site
determin
glycoprotein
roth
et
al
nucleocapsid
matrix
protein
sort
glycoprotein
requir
glycosyl
roth
et
al
green
et
al
rna
virus
bud
intracellular
site
plasma
membran
golgi
membran
bunya
virus
golgi
membran
endoplasm
reticulum
coronavirus
endoplasm
reticulum
rotavirus
bishop
holm
sort
signal
present
viral
glycoprotein
necessari
direct
protein
differ
intracellular
locat
yet
determin
differ
kinet
intracellular
transport
exampl
differ
viral
membran
glycoprotein
suggest
transport
select
see
exampl
fit
kabat
coval
alter
glycoprotein
glycosyl
glycoprotein
process
may
influenc
requir
transport
cf
guan
et
al
review
olden
et
al
achiev
known
one
theori
possibl
applic
secretori
glycoprotein
postul
interact
newli
made
glycoprotein
endogen
carbohydratebind
recogn
protein
lectin
step
requir
intracellular
transport
olden
et
al
olden
et
al
anoth
postul
glycosyl
influenc
fold
nascent
polypeptid
thu
exert
effect
intracellular
transport
gibson
et
al
see
also
section
use
postul
invok
explain
number
effect
glycosyl
inhibitor
alter
protein
conform
may
eg
basi
increas
suscept
degrad
proteolysi
nonor
differ
glycosyl
protein
olden
et
al
schwarz
datema
bienkowski
may
impair
accur
proteolyt
process
precursor
polyprotein
klenk
rott
may
caus
aggreg
nonor
differ
glycosyl
viral
glycoprotein
membran
thu
impair
effect
intracellular
transport
gibson
et
al
effect
one
may
lead
decreas
proport
even
absenc
envelop
glyco
protein
membran
viru
bud
case
prevent
bud
infect
inhibitortr
cell
would
like
emphas
scenario
appli
everi
viral
glycoprotein
instead
idiosyncrasi
viral
glycoprotein
requir
discuss
individu
viral
glycoprotein
detail
influenza
virus
code
two
membran
glycoprotein
hemagglutinin
ha
neuraminidas
na
see
fig
murphi
webster
third
membran
protein
glycosyl
lamb
et
al
ha
major
cellsurfac
antigen
involv
antigen
variat
membran
fusion
receptor
bind
murphi
webster
ha
synthes
singl
polypeptid
chain
trypsin
trypsinlik
endoproteas
host
cell
cleav
ha
posttransl
two
fragment
ha
hat
har
held
togeth
disulfid
bridg
klenk
rott
murphi
webster
carboxypeptidaselik
enzym
activ
subsequ
remov
ctermin
arg
hat
case
fowl
plagu
viru
ctermin
basic
peptid
garten
et
al
garten
klenk
cleavag
hat
result
conform
chang
nterminu
remov
cterminu
hat
wiley
amino
terminu
stretch
highli
conserv
hydrophob
amino
acid
fusion
peptid
involv
membran
fusion
activ
ha
necessari
infecti
cell
entri
see
exampl
klenk
et
al
skehel
waterfield
skehel
et
al
huang
et
al
white
et
al
white
et
al
thu
infect
requir
cleavag
ha
intact
fusion
peptid
hemagglutinin
spike
viru
membran
trimer
held
togeth
noncoval
linkag
ha
monom
consist
globular
region
contain
receptor
bind
site
consist
part
ha
stem
contain
fusion
peptid
consist
part
hat
sequenc
ha
hong
strain
contain
potenti
nglycosyl
site
ward
klenk
et
al
glycosyl
site
ha
site
seven
site
two
contain
highmannos
structur
remaind
moreprocess
complextyp
structur
wiley
one
site
occur
later
surfac
molecul
oligosaccharid
cover
ca
surfac
area
olink
oligosaccharid
occur
ha
differ
ie
differ
viru
strain
contain
oligosaccharid
addit
straindepend
differ
structur
oligosaccharid
klenk
et
al
hand
structur
analysi
individu
oligosaccharid
attach
particular
glycosyl
site
certain
ha
ha
rostock
strain
fowl
plagu
viru
show
attach
site
contain
uniqu
set
oligosaccharid
keil
et
al
neutral
antibodi
influenza
viru
direct
toward
certain
region
ha
identifi
three
dimension
structur
glycoprotein
analysi
structur
oligosaccharid
ha
show
structur
also
occur
cellular
glycoprotein
matsumoto
et
al
keil
et
al
niemann
et
al
therefor
suggest
variat
oligosaccharid
attach
site
ha
rather
variat
oligosaccharid
structur
may
play
role
antigen
variat
ha
exampl
achiev
oligosaccharid
mask
certain
region
antigen
site
ie
block
interact
antibodi
underli
polypeptid
oligosaccharid
exert
distal
effect
antigen
site
lack
oligosaccharid
skehel
et
al
alexand
elder
nevertheless
compar
immun
reactiv
antisera
prepar
ha
enzymat
deglycosyl
ha
prepar
use
endoglycosidas
f
found
oligosaccharid
sidechain
also
direct
immun
respons
epitop
influenc
directli
oligosaccharid
alexand
elder
inhibit
protein
glycosyl
dglc
glcn
fman
tunicamycin
chick
embryo
cell
infect
influenza
viru
fowl
plagueviru
caus
inhibit
product
infecti
viru
particl
schwarz
datema
one
explan
result
extens
degrad
nonglycosyl
ha
prior
transport
plasma
membran
schwarz
et
al
inde
inclus
medium
tunicamycintr
cell
proteas
inhibitor
prevent
extent
degrad
nonglycosyl
ha
threedimension
structur
ha
influenza
ahongkong
show
interestingli
number
potenti
chymotrypt
tryptic
cleavag
site
cleav
ha
partial
cover
oligosaccharid
although
rigor
exclud
degrad
unglycosyl
ha
occur
work
infectedcel
lysat
inaccur
cleavag
underor
nonglycosyl
ha
cell
treat
dglc
also
attribut
decreas
metabol
stabil
nonor
underglycosyl
ha
schwarz
klenk
klenk
rott
deoxyglucosetreat
contrast
tunicamycintreat
result
complet
unglycosyl
ha
nakamura
compan
part
explain
differ
metabol
stabil
ha
produc
tunicamycinand
dglctreat
cell
later
studi
note
nonglycosyl
number
strain
antigen
relat
fowl
plagu
viru
h
strain
synthes
presenc
tunicamycin
degrad
complet
clearli
problem
proteolyt
sensit
nonglycosyl
ha
need
resolv
quantit
term
appear
howev
inhibitortr
cell
infect
virus
synthes
noncleav
bosch
et
al
bosch
et
al
nonglycosyl
uncleav
metabol
stabl
absenc
proteas
inhibitor
basak
compan
bosch
rott
thu
mdbk
cell
infect
influenza
awsn
hon
noncleav
ha
defin
ha
molecul
infect
cell
system
cleav
hat
cleavabl
part
determin
primari
structur
peptid
connect
ha
bosch
et
al
viru
particl
product
prevent
tunicamycin
spikeand
glycoproteindefici
particl
detect
nonglycosyl
ha
presum
degrad
releas
viru
particl
medium
nakamura
compan
thu
rapid
harvest
procedur
includ
proteas
inhibitor
use
virion
intact
nonglycosyl
ha
obtain
virion
show
welldefin
undegrad
surfac
spike
indic
glycosyl
necessari
format
hatrim
basak
compan
inde
migrat
unglycosyl
uncleav
ha
plasma
membran
infect
cell
still
occur
appear
cellsurfac
inhibit
intracellular
synthesi
basak
compan
result
unglycosyl
ha
still
incorpor
rough
membran
earliest
indic
glycosyl
requir
membran
insert
membran
glycoprotein
furthermor
unglycosyl
ha
migrat
smooth
membran
fraction
plasma
membran
normal
rate
basak
compan
provid
molecul
metabol
stabl
see
cleavag
ha
subunit
smooth
membran
fraction
also
prevent
glycosyl
inhibit
cleavag
may
jeopard
metabol
stabil
unglycosyl
ha
elimin
connect
peptid
amino
acid
carboxypeptidas
howev
occur
unglycosyl
cleav
ha
least
surviv
degrad
proteolysi
avail
trim
inhibitor
allow
studi
fate
glycosyl
ha
oligosaccharid
process
matur
oligosaccharid
select
block
thu
contrast
tunicamycin
dglc
trim
inhibitor
inhibit
glycosyl
rather
inhibit
glycosyl
discuss
trim
inhibitor
deoxynojirimycin
deoxymannojirimycin
section
inhibit
glycosyl
result
underglycosyl
addit
inhibit
process
possibl
alway
rigor
exclud
assum
influenza
viru
ha
glycosyl
initi
gi
oligosaccharid
glucosetrim
appear
obligatori
step
glycoprotein
process
glucosyl
ha
occur
cell
surfac
datema
et
al
furthermor
base
structur
oligosaccharid
fowl
plagu
viru
preponder
complextyp
oligosaccharid
viral
serotyp
extens
mannos
trim
occur
well
klenk
et
al
analyz
effect
glucosidas
iinhibitor
castanospermin
influenza
viru
code
noncleav
see
found
format
viru
particl
prevent
pan
et
al
viru
obtain
cell
treat
castanospermin
major
oligosaccharid
structur
shown
scheme
ie
glcnac
show
inde
glucosetrim
prevent
howev
mannosetrim
still
occur
despit
presenc
three
glc
residu
glc
ctl
oligosaccharid
analysi
present
studi
effect
deoxynojirimycin
noncleav
influenza
viru
ha
viru
n
burk
et
al
howev
assum
drug
work
specif
studi
confirm
inhibit
glucos
trim
prevent
neither
cellsurfac
express
ha
releas
viru
inhibit
trim
innermost
glucos
residu
bromoconduritol
viral
ha
equip
oligosaccharid
structur
glcmanx
glcnac
x
complextyp
oligosaccharid
format
prevent
effect
cellsurfac
express
ha
viru
releas
viru
code
noncleav
ha
result
taken
togeth
suggest
like
inhibit
glycosyl
inhibit
glucos
trim
qualit
speak
prevent
cellsurfac
express
noncleav
ha
furthermor
result
indic
equip
noncleav
ha
highmannos
oligosaccharid
addit
deoxynojirimycin
castanospermin
bromoconduritol
cultur
infect
cell
suffici
allow
viru
product
ha
cellsurfac
express
quantit
indistinguish
untreat
infect
cell
nmethyldeoxynojirimycin
concentr
inhibit
glucosetrim
complet
almost
fulli
inhibit
complextyp
oligosaccharid
format
inhibit
viral
protein
synthesi
oligosaccharidelipid
synthesi
affect
stabil
pulselabel
viral
protein
romero
et
al
fowl
plagu
viru
format
chick
embryo
cell
inhibit
nmethyldeoxynojirimycin
fulli
infecti
viru
particl
releas
contain
partial
process
oligosaccharid
structur
glcnac
oligosaccharid
glcnac
deriv
glcnac
mannosetrim
cleavag
ha
hat
occur
smooth
membran
fraction
still
took
place
although
lower
rate
control
cell
romero
et
al
tt
addit
elimin
basic
peptid
inhibit
tunicamycintr
cell
restor
nmethyldeoxynojirimycintr
cell
cleav
ha
equip
glcnac
x
oligosaccharid
appear
metabol
stabl
presenc
bromoconduritol
intracellular
viral
ha
fulli
glycosyl
equip
glcmanx
glcnac
oligosaccharid
condit
fowl
plagu
viru
ha
cleav
hat
connect
peptid
remov
presum
due
decreas
rate
intracellular
transport
rate
cleavag
ha
decreas
datema
et
al
thu
respect
bromoconduritol
nomethyldeoxynojirimycin
gave
qualit
similar
biolog
effect
howev
cleav
product
hat
equip
glcmanx
glcnac
x
oligosaccharid
metabol
unstabl
reach
cell
surfac
although
could
detect
intracellularli
releas
infecti
viru
particl
inhibit
datema
et
al
respect
effect
cleav
ha
viru
format
reminisc
effect
tunicamycin
simplest
explan
result
uncleav
ha
metabol
stabl
infect
cell
independ
oligosaccharid
composit
wherea
cleavag
ha
equip
glcnac
yield
stabl
product
cleavag
ha
oligosaccharid
glc
manx
glcnac
yield
product
sucept
degrad
proteolysi
oligosaccharid
process
prevent
bromoconduritol
differ
biolog
effect
bromocondurltol
inhibit
glucosidas
ii
nmethyldeoxynojirimycin
deoxynojirimycin
inhibit
glucosidas
seen
sindbi
viru
rou
sarcoma
viru
see
suggest
effect
bromoconduritol
fowl
plagu
viru
may
due
nonspecif
action
drug
howev
test
effect
bromoconduritol
nmethyldeoxynojirimycin
tunicamycin
growth
human
embryo
fibroblast
datema
unpublish
result
bromoconduritol
tunicamycin
show
inhibit
cell
divis
concentr
give
antivir
effect
wherea
nomethyldeoxynojirimycin
deoxynojirimycin
show
cytotox
mi
drug
also
castanospermin
cytotox
pan
et
al
would
therefor
interest
find
anoth
inhibitor
glucosidas
ii
studi
effect
pathogen
influenza
virus
similarli
interest
question
process
pathway
ha
cleav
attain
conform
metabol
stabl
although
number
manttfor
number
glycoprotein
shown
exit
glycoprotein
endoplasm
reticulum
retard
glucos
trim
prevent
kornfeld
kornfeld
nosidas
inhibitor
avail
yet
use
resolv
question
howev
block
late
process
step
swainsonin
inhibit
mannosidas
ii
thu
substitut
complextyp
oligosaccharid
ha
hybridtyp
oligosaccharid
fowl
plagu
viru
format
unimpair
ha
cleav
appar
normal
expect
ctmannosidas
inhibitor
deoxymannojirimycin
dim
inhibit
format
influenza
viru
influenza
anw
code
noncleav
ha
elbein
et
al
palamarczyk
et
al
experi
shown
viru
glycoprotein
equip
mang
glcnac
oligosaccharid
expect
inhibit
ctmannosidas
note
none
studi
discuss
glycoprotein
process
complet
inhibit
thu
cell
treat
castanospermin
nmethyldeoxynojirimycin
mannosetrim
glcnac
oligosaccharid
still
occur
appar
complet
inhibit
achiev
inhibit
glucosidas
mannosidas
exampl
combin
castanospermin
deoxymannojirimycin
summari
effect
glycosyl
inhibitor
see
tabl
vesicular
stomat
viru
vsv
belong
rhabdovirus
like
influenza
viru
neg
strand
rna
virus
vsv
import
human
pathogen
discuss
extens
use
glycoprotein
research
use
stem
part
immens
hostrang
part
fact
code
one
glycoprotein
g
protein
major
glycoprotein
synthes
infect
cell
g
protein
two
nglycosyl
site
virusbound
protein
usual
contain
complextyp
oligosaccharid
membran
anchor
amino
acid
carboxytermin
amino
acid
protrud
viral
core
fig
olink
oligosaccharid
occur
g
protein
emerson
cell
infect
vsv
san
juan
strain
tunicamycin
almost
complet
inhibit
infecti
viru
product
leavitt
et
al
gibson
et
al
nonglycosyl
g
protein
synthes
reach
cellsurfac
extract
cell
isol
carbohydratefre
g
protein
aggreg
gibson
et
al
possibl
correl
impair
transport
nonglycosyl
g
rough
smooth
membran
infect
cell
morrison
et
al
cell
infect
vsv
orsay
strain
also
two
nglycosyl
site
show
temperatur
depend
effect
tunicamycin
viru
releas
block
infecti
virus
contain
nonglycosyl
g
protein
releas
cell
gibson
et
al
latter
condit
g
isol
infect
cell
aggreg
form
interestingli
aggreg
g
orsay
strain
deaggreg
denatur
guanidin
hydrochlorid
show
also
temperaturesensit
reaggreg
renatur
upon
dialysi
salt
thu
g
protein
slightli
differ
amino
acid
sequenc
differ
requir
glycosyl
result
interpret
propos
oligosaccharid
transfer
nascent
glycoprotein
present
protein
endoplasm
reticulum
determin
fold
polypeptid
san
juan
strain
stringent
requir
oligosaccharid
orsay
strain
proper
fold
g
essenti
intracellular
migrat
morrison
et
al
gibson
et
al
gibson
et
al
manpdol
synthesi
inhibit
section
protein
glycosyl
glcnac
thyle
cell
synthes
manpdol
cell
infect
vsv
g
protein
equip
initi
glcnac
oligosaccharid
process
kornfeld
complextyp
oligosaccharid
found
g
wild
type
thi
cell
fig
find
cell
viabl
oligosaccharid
process
rais
question
larg
precursor
oligosaccharid
surviv
evolutionari
speak
mutant
cell
line
vsv
san
juan
temperatur
sensit
vsv
orsay
furthermor
g
protein
equip
man
glcnac
pathway
lead
format
biantennari
complextyp
oligosaccharid
block
pathway
caus
process
inhibitor
enzym
defici
clone
mutant
celllin
deriv
cho
cell
defici
glcnactransferas
gottlieb
et
al
altern
pathway
pathway
preval
mous
lymphoma
celllin
defici
synthesi
manpdol
chapman
et
al
ii
glcnac
c
man
gal
neuac
r
datema
et
al
inhibitor
vsv
orsay
vsv
san
juan
tm
inhibit
teminhibit
c
peraturesensit
b
dn
cs
inhibit
inhibit
temperaturesensit
dmm
inhibit
inhibit
inhibit
swainsonin
inhibit
e
aabbrevi
tm
tunicamycin
dn
deoxynojirimycin
cs
castanospermin
dmm
deoxymannojirimycin
mutant
cho
celllin
defici
glcnactransferas
gottlieb
et
al
bviru
product
less
strongli
inhibit
c
particl
produc
infecti
ctransport
g
protein
cellsurfac
inhibit
dtransport
g
protein
celtsurfac
inhibit
temperaturesensit
b
eorsay
orsayrel
strain
refer
see
text
produc
mutant
celllin
isol
dissolv
guanidin
hydrochlorid
renatur
upon
dialysi
san
juan
g
protein
aggreg
orsay
g
protein
aggreg
either
temperatur
gibson
et
al
appar
larg
oligosaccharid
requir
prevent
aggreg
least
certain
sensit
glycoprotein
examplifi
san
juan
g
protein
advent
process
inhibitor
could
determin
san
juan
g
protein
attain
proper
conform
glucos
residu
remov
schlesing
et
al
howev
contrast
nonglycosyl
g
san
juan
g
san
juan
produc
presenc
castanospermin
deoxynojirimycin
move
cell
surfac
nevertheless
vsv
san
juan
product
decreas
presum
g
protein
glcresidu
retain
particip
viru
bud
viru
product
inhibit
either
temperatur
vsv
orsay
product
g
protein
sensit
alter
oligosaccharid
structur
affect
expect
result
cell
vsv
could
rais
presenc
swainsonin
fulli
infecti
kang
g
protein
case
equip
hybridtyp
oligosaccharid
see
fig
summari
effect
see
tabl
sindbi
viru
close
rel
semliki
forest
viru
sfv
use
extens
studi
glycoprotein
biosynthesi
anim
cell
two
virus
belong
alphavirus
subgroup
togaviru
famili
simpl
envelop
posit
strand
rna
virus
viral
nucleocapsid
virus
envelop
lipid
bilay
spike
glycoprotein
matrix
protein
found
influenza
virus
vsv
absent
fig
viral
structur
protein
gener
seri
proteolyt
cleavag
initi
cleavag
occur
translat
subgenom
mrna
first
cleavag
gener
capsid
protein
translat
signal
sequenc
form
initi
transmembran
transloc
nascent
protein
proteolyt
cleavag
gener
glycoprotein
remain
anchor
membran
translat
gener
signal
sequenc
second
glycoprotein
e
aid
synthesi
vsv
san
juan
temperaturesensit
viru
grown
mutant
chocelllin
initi
glycosyl
occur
via
process
block
stage
fig
due
defect
gicnac
transferas
vectori
transfer
glycoprotein
membran
anchor
synthes
carboxi
terminu
e
l
remain
cytoplasm
site
membran
fig
e
l
pe
glycosyl
cotransl
endoplasm
reticulum
move
endoplasm
reticulum
golgi
system
plasma
membran
el
form
complex
oligosaccharid
process
cleav
presum
golgi
membran
trypsinlik
enzym
keegstra
burk
bell
strauss
schmidt
schlessing
griffith
et
al
taba
kornfeld
bonatti
cancedda
ziemiecki
et
al
proteolyt
cleavag
pe
essenti
viru
bud
small
glycoprotein
amino
acid
lost
sindbi
viru
remain
associ
el
heterodim
sfv
simon
warren
e
l
sinbi
viru
contain
two
nglycosyl
site
rice
strauss
viru
grown
bhk
cell
chicken
embryo
cell
complextyp
oligosaccharid
occur
el
e
carri
highmannos
chain
el
complex
highmannos
chain
mayn
et
al
whether
particular
glycosyl
site
carri
complextyp
less
highmannos
process
oligosaccharid
presum
determin
larg
extent
exclus
fold
polypeptid
chain
highmannosecarri
site
less
access
process
enzym
hsieh
et
al
hsieh
et
al
hsieh
robbin
appear
locat
exclus
complextyp
oligosaccharid
carri
nglycosyl
site
conserv
alphavirus
dalgarno
et
al
make
interfer
complextyp
oligosaccharid
format
interest
problem
sindbi
virusinfect
bhk
cell
glucosetrim
inhibit
deoxynojirimycin
nmethyldeoxynojirimycin
castanospermin
bromoconduritol
cleavag
inhibit
protein
migrat
cell
surfac
expect
requir
cleavag
viru
format
releas
viru
particl
decreas
inhibitortr
cell
romero
et
al
nonglycosyl
cleav
either
howev
detect
cellsurfac
instead
nonglycosyl
sindbi
glycoprotein
seem
aggreg
intraceuul
compart
reminisc
describ
vsv
g
protein
leavitt
et
al
result
indic
pez
equip
glucosyl
highmannos
oligosaccharid
conform
make
resist
cleavag
golgiloc
proteas
previous
deduc
sfv
glycoprotein
correspond
sindbi
viru
undergo
conform
rearrang
matur
protein
kaluza
et
al
possibl
conform
chang
requir
least
glucosetrim
result
conform
make
protein
suscept
tryptic
proteas
inde
allow
glucos
trim
prevent
mannos
trim
deoxymannojirimycin
result
cleavag
pe
mcdowel
w
person
commun
interfer
protein
conform
chang
observ
glucosidaseinhibitor
treat
cell
make
understand
viru
format
cell
treat
deoxynojirimycin
temperaturesensit
summari
see
tabl
mous
hepat
viru
mhv
belong
coronavirus
famili
larg
envelop
positivestrand
rna
virus
holm
viral
envelop
contain
wide
space
spike
appear
like
corona
electron
microscop
contain
glycoprotein
cf
fig
glycoprotein
mani
respect
typic
rna
virusmembran
glycoprotein
holm
synthes
nglycosyl
proteolyt
cleav
acyl
membran
anchor
transport
plasma
membran
glycoprotein
mhv
present
uniqu
featur
viral
membran
glycoprotein
deepli
embed
membran
transport
plasma
membran
oglycosyl
acyl
niemann
klenk
holm
et
al
rottier
et
al
niemann
et
al
armstrong
et
al
et
al
function
may
relat
matrix
protein
influenza
vsv
holm
possibl
bud
coronavirus
intern
membran
rather
plasma
membran
determin
protein
accumul
intern
membran
synthesi
holm
signal
caus
el
accumul
perinuclear
membran
residu
viral
compon
perturb
golgi
apparatu
ionophor
monensin
tartakoff
prevent
oglycosyl
el
yet
viru
bud
endoplasm
reticulum
releas
infect
cell
niemann
et
al
nonglycosyl
mhv
contrast
normal
glycosyl
counterpart
transport
cellsurfac
unglycosyl
found
instead
smooth
membran
fraction
tunicamycintr
cell
repp
et
al
viru
particl
devoid
howev
releas
tunicamycintr
cell
holm
et
al
niemann
klenk
rottier
et
al
infecti
underlin
role
viral
infect
addit
hamper
intracellular
transport
inhibit
glycosyl
may
increas
suscept
nonglycosyl
protein
proteolysi
holm
et
al
rottier
et
al
interestingli
format
viru
particl
inhibit
presenc
nmethyldeoxynojirimycin
castanospermin
repp
et
al
equip
glucosyl
highmannos
oligosaccharid
appear
cell
surfac
drastic
delay
nonglycosyl
found
intracellular
smooth
membran
fraction
howev
glucosidas
inhibitor
caus
delay
intracellular
transport
also
concomit
inhibit
synthesi
increas
degrad
lesser
extent
observ
occur
tunicamycintr
cell
investig
parallel
repp
et
al
decreas
format
presenc
nmethyldeoxynojirimycin
present
rational
deceas
viru
particl
format
although
immedi
evid
glucosidas
inhibitor
could
influenc
format
el
allow
glucosetrim
inhibit
mannosetrim
hardli
effect
intracellular
transport
viru
format
repp
et
al
result
reminisc
found
envelop
rna
viru
underlin
crucial
role
glucosetrim
matur
viral
membran
glycoprotein
summari
see
tabl
role
glycosyl
oligosaccharid
process
env
protein
sever
retrovirus
studi
connect
correct
proteolyt
process
h
niemann
person
commun
effect
aabbrevi
tm
tunicamycin
mdn
nmethyldeoxynojirimycin
cs
castanospermin
dim
bnot
occur
delay
due
precursor
reach
intracellular
site
cleavag
occur
cnoninfecti
viru
particl
lack
form
dheterogen
cleavag
product
alter
molecular
weight
observ
epresum
lack
effect
virusinduc
cell
fusion
infecti
viru
format
also
shown
indirect
immunofluoresc
h
niemann
person
commun
polyprotein
precursor
envelop
glycoprotein
intracellular
migrat
glycoprotein
incorpor
virion
result
obtain
differ
differ
retrovir
system
highlight
result
confin
discuss
comparison
result
obtain
avian
retroviru
rou
sarcoma
viru
rsv
mammalian
retroviru
friend
mink
cell
focusinduc
murin
leukemia
viru
mulv
system
inhibitor
glycosyl
oligosaccharid
process
investig
thu
system
glycosyl
found
necessari
correct
proteolyt
process
stabl
product
incorpor
product
virion
tunicamycin
deoxyglucosetr
cultur
virion
releas
devoid
env
protein
schwarz
et
al
diggelman
stohrer
hunter
pinter
et
al
metabol
fate
nonglycosyl
env
protein
rsv
mulv
differ
howev
appear
rsv
protein
cleav
cleav
product
degrad
bosch
et
al
mulv
counterpart
cleav
protein
transport
cell
surfac
pinter
et
al
earlier
work
pierotti
et
al
shown
sever
monoclon
antibodi
direct
agaist
mulv
envprotein
recogn
nonglycosyl
form
wherea
antibodi
recogn
enzymat
deglycosyl
envprotein
suggest
glycosyl
induc
conform
chang
protein
facilit
effect
intracellular
transport
correct
proteolysi
allow
glycosyl
occur
prevent
oligosaccharid
trim
either
nmethyldeoxynojirimycin
bromoconduritol
deoxymannojirimycin
swainsonin
confirm
oligosaccharid
analysi
restor
correct
proteolyt
cleavag
env
protein
schmidtruppin
strain
rsv
addit
aberrantli
glycosyl
glycoprotein
rsv
incorpor
virion
infecti
releas
medium
normal
amount
bosch
et
al
contrast
oligosaccharid
process
necessari
transport
env
protein
mulv
cell
surfac
proteolyt
cleavag
shown
infect
cellcultur
treat
deoxynojirimycin
drugtreat
lead
decreas
incorpor
env
protein
extracellular
virion
decreas
viru
format
pinter
et
al
requir
oligosaccharid
process
proteolyt
cleavag
env
protein
mulv
reminisc
seen
sindbi
viru
system
see
interest
observ
mulv
env
protein
form
presenc
deoxynojirimycin
contain
complextyp
oligosaccharid
chain
pinter
et
al
env
protein
rsv
mulv
equip
normal
mainli
sialyl
complextyp
oligosaccharid
possibl
trim
glucosidas
incomplet
inhibit
deoxynojirimycin
less
potent
inhibitor
nmethyldeoxynojirimycin
romero
et
al
appear
unlik
high
concentr
drug
use
rather
possibl
consid
mulvenv
protein
glycosyl
part
nonglucosyl
highmannos
oligosaccharid
mechan
describ
system
cf
p
investig
mulv
system
use
mannosidasei
inhibitor
seem
therefor
particular
interest
retrovirus
code
oncogen
product
transform
protein
glycoprotein
glycoprotein
call
vfm
mcdonough
strain
felin
sarcoma
viru
smfesv
verb
b
avian
erythroblastosi
viru
aev
investig
regard
whether
oligosaccharid
process
essenti
role
transform
thu
smfesv
infect
cell
cultur
treat
castanospermin
nmethyldeoxynojirimycin
show
serumdepend
growth
hadwig
et
al
poor
growth
softagar
nichol
et
al
suggest
drug
prevent
transform
glycosyl
oncogen
product
seem
inde
affect
judg
chang
electrophoret
mobil
protein
protein
still
protein
kinas
activ
exhibit
cytoplasm
domain
membran
protein
process
gagfin
fusionprotein
releas
gag
protein
prevent
whether
cell
surfac
express
vfm
oncogen
product
affect
inhibit
oligosaccharid
process
clear
cf
hadwig
et
al
nichol
et
al
anyway
quantit
data
transport
glycoprotein
cell
surfac
glucosidaseinhibitortr
cell
lack
issu
resolv
time
specul
whether
intracellular
transport
cellsurfac
nichol
et
function
extraceullular
domain
hadwig
et
al
modifi
growthfactorreceptor
imped
alter
oligosaccharid
essenti
loss
transform
state
swainsonin
effect
smfesv
aev
system
cell
remain
transform
hadwig
et
al
nichol
et
al
schmidt
et
al
hand
verb
b
protein
form
cell
treat
deoxynojirimycin
pyrrolidin
abl
maintain
transform
state
schmidt
et
al
contrast
result
vfm
cell
surfac
express
turnov
oncogen
product
aev
system
treat
glucoseanalog
appear
unalt
thu
despit
similar
vfin
verb
b
product
consequ
oligosaccharid
process
dissimilar
therefor
seem
import
determin
whether
trim
inhibitor
inde
ident
effect
oligosaccharid
either
system
done
respect
gener
properti
biogenesi
membran
glycoprotein
envelop
dna
virus
resembl
rna
virus
cf
section
biosynthesi
nlink
oligosaccharid
appear
carri
hostcel
enzym
even
larg
dna
virus
campadellifium
serafinicessi
initi
glycosyl
asn
residu
cotransl
event
occur
endoplasm
reticulum
nlink
oligosaccharid
occur
envelop
dna
virus
olink
oligosaccharid
occur
herp
section
poxviru
glycoprotein
shida
dale
fatti
acyl
demonstr
occur
number
rna
virusmembran
glycoprotein
far
demonstr
one
herp
simplex
virusspecifi
glycoprotein
johnson
spear
gener
glycoprotein
proteolyt
cleavag
polyprotein
precursor
characterist
properti
sever
rna
viru
glycoprotein
demonstr
dnaviru
glycoprotein
three
famili
herpetovirida
poxvirida
hepadnavirida
contain
envelop
dna
virus
membran
glycoprotein
structur
compon
poxvirus
acquir
outer
envelop
bud
process
matur
golgi
complex
payn
kristensson
payn
herpesvirus
bud
inner
lamella
nuclear
membran
virion
subsequ
transfer
cell
surfac
secret
extracellular
fluid
roizman
furlong
roizman
due
lack
suitabl
permiss
cell
cultur
littl
known
morpholog
event
hepadnaviru
multipl
recent
review
see
howard
also
nonenvelop
dna
virus
adenovirus
encod
membran
glycoprotein
protein
like
take
part
infecti
process
vivo
least
adenovirus
nonenvelop
dna
virus
also
potenti
target
glycosyl
inhibitor
discuss
role
glycosyl
replic
herp
simplex
viru
hsv
import
realiz
hsv
bud
nuclear
envelop
plasma
membran
ii
hsv
specifi
glycoprotein
equip
nan
olink
oligosaccharid
iii
genet
capac
herp
virus
least
time
larger
envelop
rna
virus
inde
hsv
specifi
sever
antigen
distinct
glycoprotein
judg
larg
number
gene
product
unknown
biolog
properti
theoret
possibl
hsv
might
specifi
nonstructur
factor
glycosyl
transferas
influenc
structur
proteinassoci
oligosaccharid
hsv
vivo
resid
latent
infect
cell
long
period
time
littl
viral
protein
synthesi
glycosyl
see
review
hill
howev
rapid
cytolyt
infect
hsv
infect
cultur
cell
enabl
detail
studi
phase
infecti
cycl
infect
initi
bind
one
glycoprotein
viral
envelop
receptor
permiss
cell
svennerholm
person
commun
fuller
spear
hsv
type
caus
predominantli
oralfaci
infect
bind
receptor
mainli
associ
genit
herp
vahln
et
al
penetr
hsv
preced
fusion
process
appear
occur
cell
surfac
endosom
spear
role
hsv
glycoprotein
adsorpt
penetr
discuss
follow
fusion
nucleocapsid
transport
nuclear
membran
viral
dna
transfer
nucleu
transcript
dna
replic
take
place
roizman
furlong
roizman
sever
viru
protein
synthes
cytoplasm
includ
capsomer
dnabind
protein
transport
back
nucleu
also
assembl
nucleocapsid
occur
roizman
furlong
roizman
bud
herp
viru
occur
inner
membran
nuclear
lamella
roizman
furlong
roizman
undoubtedli
must
occur
massiv
transport
viral
glycoprotein
synthes
cytoplasm
membran
nucleu
littl
known
transport
mechan
viral
glycoprotein
addit
transport
plasma
membran
spear
nuclei
seem
contain
higher
proport
lessprocess
glycoprotein
ie
glycoprotein
predominantli
highmannos
chain
plasma
membranebound
glycoprotein
suggest
complet
process
nlink
oligosaccharid
prerequisit
transport
nuclear
membran
compton
courtney
fact
larg
proport
nucleusassoci
hsvglycoprotein
found
carlohydratedefici
precursor
may
glycosyl
posttransl
compton
courtney
sever
mechan
propos
viral
egress
cytoplasm
cell
surfac
roizman
furlong
spear
activ
role
morpholog
biochem
aspect
hsv
infect
permiss
cell
review
roizman
furlong
roizman
r
dama
et
al
spear
mors
et
al
reuchan
et
al
frink
et
al
para
et
al
marsden
et
al
roizman
et
al
buckmast
et
al
spear
mcgeoch
et
al
swain
et
al
ackermann
et
al
richman
et
al
golgi
apparatu
seem
requir
egress
arrest
monensin
ionophor
disturb
golgimedi
intracellular
traffic
johnson
spear
indic
hsv
exist
two
distinct
type
although
hsvi
differ
biolog
properti
genom
organ
ident
allow
construct
viabl
intertyp
recombin
halliburton
virus
specifi
least
five
distinct
glycoprotein
design
gb
gc
gd
ge
gg
hsv
glycoprotein
review
spear
appear
genet
map
fig
loci
specifi
glycoprotein
mapposit
genom
moreov
variant
particular
glycoprotein
exhibit
consider
similar
biolog
antigen
properti
amino
acid
sequenc
spite
similar
glycoprotein
also
display
typespecif
antigen
domain
recogniz
monoclon
antibodi
variat
degre
typespecif
depend
glycoprotein
studi
norrild
dowbenko
laskey
spear
summari
properti
hsv
specifi
glycoprotein
shown
tabl
hsvglycoprotein
contain
nlink
oligosaccharid
complextyp
high
rnannos
type
highmannos
oligosaccharid
associ
mainli
partial
fuller
spear
svennerholm
b
jeansson
vahln
lyck
e
submit
olofsson
et
al
b
olofsson
et
al
bauck
spear
spear
nobl
et
al
serafinicessi
et
al
olofsson
et
al
buckmast
et
al
johnson
spear
littl
et
al
abbrevi
hpa
helix
pomatia
lectin
process
glycoprotein
precursor
detect
infect
cell
glycoprotein
b
differ
hsv
glycoprotein
also
fulli
glycosyl
end
product
contain
high
mannos
oligosaccharid
wensk
et
al
serafinicessi
campadellifium
campadellifium
et
al
base
lectin
affin
gelfiltr
analysi
suggest
complextyp
oligosaccharid
gc
biand
triantennari
campadellifium
serafinicessi
larger
oligosaccharid
may
present
kumarasami
blough
data
hsvglycoprotein
avail
studi
hsv
glycoprotein
produc
cell
line
defect
glycosyl
machineri
indic
hostcel
enzym
involv
nglycosyl
campadellifium
et
al
campadellifium
serafinicessi
serafinicessi
et
al
howev
differ
kinet
properti
sialyland
galactosyl
transfer
extract
hsvinfect
cell
compar
extract
uninfect
cell
suggest
hsvinfect
might
influenc
oligosaccharid
structur
least
hsv
glycoprotein
contain
olink
oligosaccharid
addit
nlink
one
wensk
courtney
olofsson
et
al
olofsson
et
al
olofsson
et
al
norrild
pedersen
spear
serafinicessi
et
al
glycoprotein
olink
oligosaccharid
affin
galnacspecif
lectin
helix
pomatia
hpa
olofsson
et
al
olofsson
et
al
addit
olink
oligosaccharid
contain
termin
neuac
neuacgal
dallolio
et
al
johnson
spear
olofsson
et
al
olink
oligosaccharid
still
form
infect
cell
treat
tunicamycin
indic
synthesi
affect
absenc
nlink
oligosaccharid
olofsson
et
al
although
specifi
glycoprotein
contain
oglycosyl
oligosaccharid
spear
specifi
glycoprotein
gc
bind
hpa
howev
hpabind
oligosaccharid
also
found
one
singl
glycoprotein
interestingli
olofsson
et
al
host
cellcont
hpabind
glycoconjug
increas
time
hsv
infect
due
biosynthesi
gc
olofsson
et
al
b
yet
conclud
hsvspecifi
glycosyl
transferas
engag
biosynthesi
proport
hpabind
olofsson
jeansson
prepar
oglycosyl
oligosaccharid
depend
cell
type
use
infect
olink
oligosaccharid
rel
small
dito
tetrasaccharid
largest
one
sialyl
arrang
multioligosaccharid
cluster
glycoprotein
molecul
thu
suggest
could
contain
mani
small
olink
oligosaccharid
organ
therefor
much
resembl
observ
respiratori
syncyti
viru
glycoprotein
gruber
levin
wertz
et
al
ball
et
al
sever
line
indirect
evid
olofsson
et
al
suggest
peptid
sequenc
amino
acid
essenti
acquisit
olink
oligosaccharid
gc
recent
studi
shown
larg
tunicamycinand
pronaseresist
hpabind
glycopeptid
report
olofsson
et
al
compos
fact
sever
small
olink
oligosaccharid
presum
similar
size
structur
report
sever
report
inhibitor
nglycosyl
block
product
infecti
hsv
thu
tunicamycin
reduc
yield
infecti
viru
factor
factor
pizer
et
al
ktz
et
al
ktz
et
al
courtney
et
al
despit
dramat
decreas
infecti
particl
number
envelop
hsv
particl
significantli
decreas
indic
product
morpholog
intact
envelop
particl
without
infect
courtney
et
al
pizer
et
al
katz
et
al
found
hsvparticl
produc
presenc
deoxyglucos
tunicamycin
adsorb
permiss
cell
equal
well
tthe
suffix
use
distinguish
specifi
glycoprotein
respect
infecti
viru
untreat
cell
suggest
attachmentfunct
hsv
impair
absenc
nlink
oligosaccharid
spivack
et
al
svennerholm
et
al
liand
abil
hsv
penetr
plasma
membran
markedli
reduc
inhibit
nlink
oligosaccharid
format
thu
synthesi
transport
intraceuular
local
viru
bud
proper
function
viral
cellattach
compon
appear
depend
presenc
nlink
oligosaccharid
contrast
fusion
activ
hsv
glycoprotein
must
abolish
absenc
nlink
oligosaccharid
knowl
person
glycosyl
inhibitor
first
use
antivir
agent
vivo
report
deoxyglucos
success
treatment
herp
simplex
virusinduc
kerat
rabbit
ray
et
al
result
prompt
studi
human
appear
durat
genit
hsv
infect
consider
reduc
deoxyglucos
treatment
blough
giuntoli
howev
signific
find
question
studi
durat
lesion
virusshed
consider
longer
placebotr
subject
also
deoxyglucosetr
subject
untreat
patient
genit
hsv
infect
corey
holm
one
reason
could
cream
base
contain
surfact
similar
use
vehicl
studi
blough
giuntoli
may
prolong
durat
genit
herp
corey
holm
thu
clear
studi
human
would
requir
demonstr
potenti
glycosyl
inhibitor
treatment
genit
herp
infect
human
howev
later
studi
fail
show
effect
deoxyglucos
hydroxynorvalin
cours
herp
infect
anim
model
hsiung
et
al
kern
et
al
shannon
et
al
gordon
et
al
find
discourag
studi
effect
glycosyl
inhibitor
human
genit
herp
infect
reason
lack
effect
deoxyglucos
known
possibl
drug
potent
enough
tunicamycin
might
interest
altern
light
observ
effect
vivo
note
p
also
possibl
anim
model
deoxyglucos
metabol
antivir
activ
metabolit
gdpdgic
see
also
section
fate
individu
viral
glycoprotein
hsvinfect
cell
trate
tunicamycin
need
consid
date
three
specifi
glycoprotein
gc
gb
gd
investig
extens
respect
differ
consequ
inhibit
glycosyl
note
instead
transport
cell
surfac
gb
synthes
presenc
tunicamycin
accumul
intracellularli
degrad
norrild
pedersen
glorioso
et
al
analog
vsv
g
protein
see
section
propos
unglycosyl
form
gb
might
aggreg
transport
plasma
membran
intracellular
locat
contrast
gc
produc
presenc
tunicamycin
readili
transport
plasma
membran
antigen
activ
preserv
extent
despit
absenc
nlink
oligosaccharid
norrild
pedersen
glorioso
et
al
spear
gc
contain
consider
amount
olink
oligosaccharid
may
help
prevent
aggreg
proteolyt
degrad
gc
lack
nlink
oligosaccharid
olofsson
et
al
johnson
spear
olofsson
et
al
dallolio
et
al
whether
unglycosyl
gd
transport
cell
surfac
appear
celltyp
depend
glorioso
et
al
norrild
pedersen
peak
et
al
adsorpt
penetr
process
hsv
seem
mediat
one
glycoprotein
svennerholm
person
commun
fuller
spear
nobl
et
al
undoubtedli
gc
play
import
role
virusabsorpt
protein
adsorpt
hsv
permiss
cell
block
monoclon
gcspecif
antibodi
fuller
spear
svennerholm
person
commun
howev
gcneg
hsv
strain
abil
adsorb
product
infect
permiss
cell
must
least
one
glycoprotein
hsv
envelop
abil
initi
attach
base
inhibit
experi
monoclon
antibodi
seem
like
gd
probabl
also
ge
might
involv
attach
fuller
spear
concept
two
hsv
glycoprotein
cooper
attach
process
support
find
gcneg
hsv
mutant
adsorb
less
effect
wild
type
strain
svennerholm
person
commun
present
known
viral
attach
glycoprotein
present
envelop
hsv
particl
tunicamycintr
cell
howev
assumpt
gc
major
import
attach
protein
accord
find
glycoprotein
readili
transport
maintain
antigen
activ
variou
locat
also
tunicamycintr
cell
norrild
pedersen
glorioso
et
al
mention
penetr
hsv
requir
fusion
studi
induc
syncytia
format
found
gb
gd
fusogen
properti
nobl
et
al
manservigi
et
al
littl
et
al
least
gb
seem
essenti
penetr
hsvi
temperaturesensit
gbneg
mutant
produc
nonpermiss
temperatur
abil
adsorb
permiss
cell
penetr
manservigi
et
al
littl
et
al
sarmiento
et
al
role
gd
penetr
unknown
describ
gb
produc
presenc
tunicamycin
accumul
intracellularli
transport
plasma
membran
norrild
pedersen
glorioso
et
al
nucleu
one
probabl
explan
lack
infect
hsv
produc
presenc
tunicamycin
unglycosyl
gb
integr
envelop
particl
therefor
lack
abil
infect
cell
effect
oligosaccharid
process
inhibitor
castanospermin
deoxynojirimycin
bromoconduritol
mannodeoxynojirimycin
swainsonin
hsvinfect
cell
investig
describ
rna
virus
interfer
earli
process
step
glucosidas
inhibitor
sever
affect
fate
viral
membran
glycoprotein
infecti
virusform
wherea
interfer
late
step
mannosidas
inhibitor
usual
reduc
format
infecti
viru
role
process
hsv
releas
instead
studi
celllin
defici
glycosyl
transferas
cell
use
bhkcell
mutant
ric
r
lack
almost
complet
glcnac
transferas
ric
r
partial
defect
golgi
enzym
engag
addit
peripher
sugar
hugh
et
al
narasimhan
et
al
thu
ric
r
cell
contain
less
one
percent
glcnac
transferas
activ
normal
cell
ric
r
cell
contain
glcnac
transfers
ii
galactosyl
transferas
normal
bhk
cell
hugh
et
al
gcdefici
hsv
strain
grown
ric
k
cell
electrophoret
mobil
glycoprotein
shift
glycopeptid
pronasedigest
consist
mainli
high
mannos
partiallyprocess
preferenti
monosialyl
complextyp
oligosaccharid
campadellifium
et
al
campadellifium
serafinicessi
serafiicessi
et
al
glycoprotein
hsvinfect
ric
r
cell
analyz
similar
less
pronounc
effect
observ
campadellifium
serafinicessi
serafinicessi
et
al
appear
least
fulli
process
hsv
glycoprotein
determin
elecrophoret
mobil
suggest
process
nglycosyl
oligosaccharid
complet
least
fraction
glycoprotein
campadellifium
serafinicessi
serafinicessi
et
al
addit
olink
oligosaccharid
seem
impair
cell
two
differ
effect
found
cell
use
studi
biolog
effect
partial
inhibit
process
nlink
oligosaccharid
first
time
lag
appear
intracellular
infecti
viru
prolong
mutant
cell
line
campadellifium
et
al
campadellifium
serafinicessi
serafinicessi
et
al
thu
consider
infecti
viru
found
mutant
cell
line
normal
bhk
cell
hr
post
infect
differ
disappear
hr
post
infect
serafinicessi
et
al
second
egress
newli
produc
viru
significantli
lower
mutant
celllin
normal
cell
campadellifium
et
al
serafinicessi
et
al
would
impli
effect
releas
intracellular
infecti
hsv
infect
cell
depend
process
nlink
oligosaccharid
campdellifium
serafinicessi
could
cours
verifi
use
process
inhibitor
castanospermin
swainsonin
block
egress
infecti
envelop
hsv
also
occur
presenc
monensin
spear
howev
monensin
clear
whether
block
due
absenc
fulli
process
oligosaccharid
due
direct
block
golgimedi
intracellular
transport
cf
discuss
mous
hepat
viru
p
effect
glycosyl
inhibitor
summar
tabl
indic
tabl
gel
bind
fc
posit
immunoglobulin
igg
bauck
spear
spear
gc
l
may
act
receptor
factor
complement
system
friedman
et
al
function
necessari
replic
viru
cell
cultur
spear
although
proven
could
import
interplay
hsv
host
thu
receptor
implic
take
part
regul
immun
respons
review
see
egwang
befu
introduc
surfac
infect
cell
hsv
might
interfer
mechan
activ
gc
sensit
sialidas
treatment
carbohydr
structur
must
least
part
respons
gc
smiley
friedman
activ
relev
pathogen
hsv
potenti
target
glycosyl
inhibitor
two
glycosyl
inhibitor
act
hsvinfect
cell
uninfect
cell
cell
infect
rna
virus
report
bi
amidino
hydrazon
deriv
see
section
p
presum
inhibit
step
prior
transfer
lipidlink
oligosaccharid
polypeptid
serafinicessi
campadellifium
consequ
benzhydrazon
pronounc
effect
viral
infect
explan
avail
benzhydrazon
inhibit
glycosyl
hsvinfect
cell
see
also
p
b
bromovinyldeoxyuridin
bvdu
inhibitor
hsvdna
synthesi
also
affect
electrophoret
mobil
bovin
herp
viru
glycoprorein
misra
et
al
later
similar
effect
report
hsvi
siegel
et
al
reason
bvdu
activ
herpesvirusinfect
cell
must
phosphoryl
order
exert
inhibitori
effect
dna
replic
protein
glycosyl
de
clercq
misra
et
al
siegel
et
al
phosphoryl
accomplish
uninfect
cell
due
lack
suitabl
enzym
howev
due
broad
specif
herpesvirusspecifi
thymidinekinas
bvdu
phosphoryl
infect
cell
de
clercq
hsvlinfect
cell
bvdu
exert
two
effect
protein
glycosyl
first
synthesi
lipidlink
oligosaccharid
decreas
somewhat
fullsiz
lipidlink
oligosaccharid
still
made
olofsson
et
al
clear
whether
effect
thymidinekinasedepend
second
galactos
incorpor
drastic
reduc
effect
depend
thymidinekinas
express
caus
major
increas
electrophoret
mobil
gc
viral
glycoprotein
bvdu
ad
infect
cultur
dna
synthesi
interestingli
bvdu
also
affect
synthesi
olink
oligosaccharid
hsvinfect
cell
olofsson
et
al
mention
gc
contain
two
major
class
olink
oligosaccharid
bind
hpa
probabl
termin
galnac
bind
wga
contain
termin
neuacgal
olofsson
et
al
found
bvdutreat
hsvinfect
cell
promin
increas
amount
hpabind
oligosaccharid
decreas
amount
wgabind
oligosaccharid
also
case
data
compat
inhibit
galactos
addit
inhibitori
effect
bvdu
mainli
involv
termin
step
synthesi
oligosaccharid
seem
like
effect
bvdu
glycosyl
minor
import
promin
antiherp
activ
cell
cultur
compound
possibl
implic
virusspecif
inhibit
olink
oligosaccharid
discuss
section
bvdu
inhibit
galactos
transfer
clear
action
glycosyl
inhibitor
human
herp
virus
hsv
studi
detail
howev
electrophoret
mobil
radiolabel
glycoprotein
cytomegaloviru
varizellazost
viru
epsteinbarr
viru
ebv
increas
consequ
tunicamycin
treatment
suggest
presenc
nlink
oligosaccharid
glycoprotein
pereira
edson
thorleylawson
morgan
et
al
montalvo
addit
synthes
presenc
high
concentr
tunicamycin
consider
amount
glcn
still
incorpor
glycoprotein
suggest
presenc
olink
oligosaccharid
glycoprotein
human
herpesvirus
similar
find
also
report
bovin
herp
viru
misra
et
al
detail
pictur
effect
inhibit
format
nlink
oligosaccharid
infecti
cycl
far
obtain
ebv
huttfletch
et
al
thu
presenc
tunicamycin
seemingli
intact
envelop
ebv
particl
without
infect
form
result
resembl
much
result
obtain
hsv
system
see
p
tabl
spivack
et
al
svennerholm
et
al
moreov
found
hsv
envelop
particl
adsorb
permiss
cell
normal
rate
compar
untreat
viru
abil
attach
viru
penetr
plasma
membran
strongli
reduc
consequ
tunicamycin
treatment
huttfletch
et
al
similar
hsv
ebv
suggest
similar
protein
mediat
fusion
ebv
hsv
point
hsvspecifi
glycoprotein
b
involv
viral
penetr
sarmiento
et
al
predict
sequenc
ebvspecifi
glycoprotein
part
similar
sequenc
hsv
glycoprotein
b
pellet
et
al
baer
et
al
find
tunicamycinsensit
ebv
hsv
penetr
immunolog
crossreact
gb
suggest
two
glycoprotein
perform
similar
function
ie
take
part
penetr
hsv
ebv
respect
huttfletch
et
al
glycoprotein
amino
acid
homolog
andor
immunolog
crossreact
gb
also
report
herpesvirus
bovin
mammil
viru
varicellazost
viru
norrild
et
al
shirki
et
al
seem
reason
assum
counterpart
gb
virus
peform
similar
function
gb
glycoprotein
depend
nlink
oligosaccharid
proper
express
biolog
properti
true
also
infect
herpesvirus
block
glycosyl
inhibitor
tunicamycin
effect
glycosyl
inhibitor
multipl
dna
virus
studi
exens
poxviru
vaccinia
viru
replic
shown
inhibit
deoxyglucos
glucosamin
payn
kristensson
vaccinia
viru
occur
two
type
infecti
particl
call
intraceuular
nake
vaccinia
extracellular
envelop
vaccinia
appleyard
et
al
like
extracellular
form
involv
dissimin
vivo
infect
payn
glucosamin
deoxyglucos
concentr
mm
result
moder
decreas
infect
infecti
intracellular
viru
although
number
intracellular
physic
particl
unaffect
payn
kristensson
reduct
infect
associ
decreas
incorpor
radiolabel
monosaccharid
glycoprotein
molecular
weight
essenti
infect
particl
payn
kristensson
product
extracellular
infecti
particl
hand
decreas
treatment
mm
inhibitor
electron
microscopi
indic
acquisit
intracellular
particl
doublemembran
structur
necessari
format
extracellular
particl
inhibit
glucosamineand
deoxyglucosetreat
payn
kristensson
therefor
possibl
glycosyl
inhibitor
potenti
arrest
replic
poxviru
also
vivo
due
lack
suitabl
permiss
cell
cultur
system
studi
effect
glycosyl
inhibitor
hepat
b
viru
avail
cho
cell
transfect
plasmid
contain
hepat
b
viru
hbsag
gene
found
tunicamycin
expect
prevent
addit
nlink
oligosaccharid
newli
synthes
polypeptid
pizer
et
al
hbsag
normal
tend
aggreg
togeth
membran
lipid
secret
empti
viruslik
vesicl
transfect
cell
possibl
get
least
inform
effect
glycosyl
releas
hepat
bparticl
thu
presenc
tunicamycin
vesicl
still
form
although
contain
nonglycosyl
hbsag
data
suggest
glycosyl
hbsag
may
strict
requir
releas
envelop
hepat
b
particl
although
adenovirus
lack
envelop
consequ
strictli
depend
glycoprotein
replic
cell
cultur
pertin
discuss
possibl
effect
glycosyl
inhibitor
replic
adenovirus
name
shown
one
transcript
unit
human
adenoviru
type
encod
membran
glycoprotein
appar
molecular
weight
walter
maizel
ishibasi
maizel
soon
replic
glycoprotein
appear
plasma
membran
storch
maizel
chin
maizel
signa
et
al
shown
glycoprotein
molecular
organ
similar
glycophorin
hla
antigen
persson
et
al
moreov
high
degre
homolog
hladr
heavi
chain
chatterje
maizel
although
gene
encod
glycoprotein
may
exclud
without
affect
adenoviru
growth
cell
cultur
reason
believ
glycoprotein
play
role
strategi
adenoviru
infect
natur
host
chatterje
maizel
shown
section
matur
envelop
virus
seem
affect
block
process
nlink
oligosaccharid
level
mannosidas
ii
exampl
swainsonin
yet
mani
complextyp
oligosaccharid
viral
glycoprotein
process
past
stage
biolog
role
termin
glycosyl
viral
glycoprotein
test
use
biolog
function
section
product
infecti
viru
particl
cell
cultur
measur
part
lifecyl
viru
consid
exampl
fate
viru
vivo
seen
section
hsieh
et
al
sindbi
viru
grown
mosquito
cell
equip
highmannos
oligosaccharid
mosquito
cell
contain
termin
sialyland
galactosyl
trasferas
studi
vivo
show
mosquito
cellgrown
sindbi
viru
clear
much
faster
blood
mice
infect
intraven
bhkcellgrown
viru
hirsch
et
al
contain
normal
set
sialyl
complextyp
oligosaccharid
see
section
analysi
system
show
clearanc
vivo
complementdepend
altern
complement
pathway
activ
sialic
acidcontain
particl
hirsch
et
al
word
analysi
sindbi
viru
vivo
show
role
termin
glycosyl
viral
glycoprotein
inde
consid
like
termin
glycosyl
nlink
oligosaccharid
synthesi
olink
oligosaccharid
see
also
viral
glycoprotein
shown
near
futur
import
viral
spread
pathogenesi
evid
nonvir
system
support
notion
exampl
oligosaccharid
cellsurfac
presum
involv
recognit
event
associ
tumor
invas
metastasi
see
exampl
read
hutchi
smet
van
beek
thu
b
murin
melanoma
cell
treat
swainsonin
pulmonari
colon
iv
inject
cell
inhibit
humphri
et
al
also
experiment
pulmonari
metastati
inhibit
adenocarcinoma
cell
line
treat
sialyl
transferas
inhibitor
kijimasuda
et
al
see
also
although
swainsonin
toxic
high
concentr
see
novikoff
et
al
immunomodul
activ
swainsonin
shown
vivo
wihout
overt
toxic
kino
et
al
thu
immunodefici
mice
swainsonin
restor
capac
produc
antibodi
inhibit
growth
sarcoma
reduc
lung
metastasi
melanoma
kino
et
al
last
interfer
process
nlink
oligosaccharid
tumor
cell
deoxynojirimycin
deoxymannojirimycin
tumor
cell
decreas
suscept
lysi
yinterferonactiv
macrophag
mercurio
show
role
nlink
complextyp
oligosaccharid
recognit
event
note
experi
possibl
oligosaccharideprocess
inhibitor
cytotox
see
p
consid
interf
termin
glycosyl
antivir
purpos
worth
take
account
carbohydr
moieti
hostplasma
membran
glycoprotein
degrad
faster
protein
moieti
tauber
et
al
short
halfliv
termin
sugar
whether
caus
serum
glycosidas
recycl
plasma
membran
glycoprotein
allow
possibl
reglycosyl
host
glycoprotein
inhibitor
termin
glycosyl
clear
serum
addit
antivir
purpos
inhibitor
act
virusinfect
cell
develop
minim
toxic
problem
virusspecif
glycosyltransferas
inhibitor
sake
argument
inhibitor
sugar
nucleotid
transloc
cf
capasso
hirschberg
could
form
virusinfect
cell
follow
activ
virusinduc
enzym
analog
format
herp
viral
dna
polymeras
inhibitor
follow
activ
herp
viral
thymidin
kinas
cf
de
clercq
thu
could
shown
e
bvdu
ad
dna
synthesi
infect
cell
inhibit
galactosyl
nand
olink
oligosaccharid
olofsson
et
al
effect
seen
cell
infect
tkdefici
strain
see
p
although
bvdu
specif
glycosyl
inhibitor
although
lnon
bvdu
inhibit
galactosyl
result
show
potenti
nucleosid
analog
glycosyl
inhibitor
lack
specif
inhibitor
olink
oligosaccharid
preclud
assess
role
divers
biolog
system
howev
recent
mutant
celllin
describ
defect
udpgaland
udpgalnac
kingsley
et
al
celllin
certainli
use
studi
role
olink
oligosaccharid
viral
glycoprotein
consid
interfer
format
olink
oligosaccharid
certain
olink
oligosaccharid
hsv
glycoprotein
may
special
interest
review
detail
section
one
hsvi
one
specifi
glycoprotein
contain
olink
oligosaccharid
unusu
lectinbind
properti
initi
oglycosyl
oligosaccharid
affin
helix
pomatia
lectin
hpa
bind
termin
galnac
recogn
recent
also
structur
affin
peanut
lectin
pna
main
specif
gal
ill
galnac
galnacspecif
lectin
vicia
villosa
detect
two
hsvspecifi
glycoprotein
olofsson
et
al
olofsson
jeansson
prepar
find
oligosaccharid
viral
glycoprotein
interest
normal
restrict
amount
glycoconjug
cell
surfac
bind
lectin
mention
appear
glycoconjug
seem
correl
certain
phase
differenti
especi
lymphoid
cell
one
consequ
three
lectin
may
use
sort
lymphocyt
differ
function
class
suggest
carbohydr
antigen
expos
cell
surfac
could
serv
recognit
structur
essenti
induct
proper
immun
respons
gahmberg
andersson
conzelmann
kornfeld
reisner
et
al
sharon
nakamura
et
al
et
al
kimura
et
al
pink
due
lectin
crossreact
hsv
glycoprotein
aforement
carbohydr
antigen
specif
variou
lymphocyt
tempt
specul
task
hsvinduc
glycoprotein
way
interfer
immun
respons
specif
inhibitor
olink
oligosaccharid
synthesi
would
enabl
test
role
oligosaccharid
primari
secondari
antihsv
immun
respons
inhibitor
termin
nglycosyl
evid
biolog
effect
olink
oligosaccharid
look
system
vivo
cell
cultur
system
see
context
mention
although
mutant
strain
defici
hpabind
glycoprotein
gc
multipli
cultur
cell
almost
well
wild
type
strain
clinic
gcdefici
isol
found
five
consecut
strain
author
laboratori
find
fact
illustr
biolog
signific
hpabind
olink
oligosaccharid
look
virushost
organ
level
rather
virushost
cell
level
